

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|-----------|--|
| (51) International Patent Classification ⁶ : C12N 5/10, 5/08, G01N 33/50, A61K 48/00 | | A2 | (11) International Publication Number: WO 97/29183 |
| | | | (43) International Publication Date: 14 August 1997 (14.08.97) |
| (21) International Application Number: PCT/US97/02063 (22) International Filing Date: 7 February 1997 (07.02.97) (30) Priority Data: 60/011,433 8 February 1996 (08.02.96) US (60) Parent Application or Grant (63) Related by Continuation US 60/011,433 (CIP) Filed on 8 February 1996 (08.02.96) (71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Bethesda, MD 20892 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): HWU, Patrick [US/US]; 11419 Commonwealth Drive #202, Rockville, MD 20852 (US). REEVES, Mark [US/US]; 23180 Palm Avenue, Grand Terrace, CA 92313 (US). ROSENBERG, Steven, A. [US/US]; 10104 Inn Gate Road, Potomac, MD 20854 (US). | | | (74) Agents: WEBER, Kenneth, A. et al.; Townsend and Townsend and Crew L.L.P., 8th floor, Two Embarcadero Center, San Francisco, CA 94111 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i> |
| (54) Title: METHODS AND COMPOSITIONS FOR TRANSFORMING DENDRITIC CELLS AND ACTIVATING T CELLS | | | |
| (57) Abstract Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen presenting cell which activates T cells against MHC class I-antigen targets. Kits, assays and therapeutics are based upon the activation of T cells by the recombinant dendritic cell. Cancer, viral infections and parasitic infections are all ameliorated by the recombinant dendritic cells, or corresponding activated T cells. Therapeutic compositions and pharmaceutical compositions are provided. | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AM | Armenia | GB | United Kingdom | MW | Malawi |
| AT | Austria | GE | Georgia | MX | Mexico |
| AU | Australia | GN | Guinea | NE | Niger |
| BB | Barbados | GR | Greece | NL | Netherlands |
| BE | Belgium | HU | Hungary | NO | Norway |
| BF | Burkina Faso | IE | Ireland | NZ | New Zealand |
| BG | Bulgaria | IT | Italy | PL | Poland |
| BJ | Benin | JP | Japan | PT | Portugal |
| BR | Brazil | KE | Kenya | RO | Romania |
| BY | Belarus | KG | Kyrgyzstan | RU | Russian Federation |
| CA | Canada | KP | Democratic People's Republic of Korea | SD | Sudan |
| CF | Central African Republic | KR | Republic of Korea | SE | Sweden |
| CG | Congo | KZ | Kazakhstan | SG | Singapore |
| CH | Switzerland | LI | Liechtenstein | SI | Slovenia |
| CI | Côte d'Ivoire | LK | Sri Lanka | SK | Slovakia |
| CM | Cameroon | LR | Liberia | SN | Senegal |
| CN | China | LT | Lithuania | SZ | Swaziland |
| CS | Czechoslovakia | LU | Luxembourg | TD | Chad |
| CZ | Czech Republic | LV | Latvia | TG | Togo |
| DE | Germany | MC | Monaco | TJ | Tajikistan |
| DK | Denmark | MD | Republic of Moldova | TT | Trinidad and Tobago |
| EE | Estonia | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | UG | Uganda |
| FI | Finland | MN | Mongolia | US | United States of America |
| FR | France | MR | Mauritania | UZ | Uzbekistan |
| GA | Gabon | | | VN | Viet Nam |

METHODS AND COMPOSITIONS FOR TRANSFORMING DENDRITIC CELLS AND ACTIVATING T CELLS

Cross Reference To Related Applications

This application is a continuation-in-part of Provisional U.S. application
10 USSN 60/011,433. This application claims priority to USSN 60/011,433, filed February
8, 1996.

BACKGROUND OF THE INVENTION

T cells mediate most forms of cellular immunity, including cell
lympholysis, delayed type hypersensitivity (DTH), transplantation rejection, and allograft
15 rejection. An introduction to T cells and cell mediated immunity is found in Paul (1993)
Fundamental Immunology, Third Edition Raven Press, New York, NY and the references
cited therein.

Typical T cells do not respond to free antigenic peptides. Instead, T cells
interact with a specialized set of cell surface proteins (the class I and class II major
20 histocompatibility complexes, or MHC) which present antigens on the surface of cells.
Cytotoxic T cells are induced to proliferate by specialized antigen presenting cells such as
macrophage and dendritic cells which present antigenic peptides on their cellular surfaces
in conjunction with MHC molecules. T cells are induced by these antigen presenting
cells to recognize corresponding antigens expressed on MHC antigens on the surface of
25 target cells. T cells destroy these target cells.

The T cell recognizes the antigen in the form of a polypeptide fragment
bound to the MHC class I molecules on target cells, rather than the intact polypeptide
itself. The polypeptide is endogenously synthesized by the cell, and a portion of the
polypeptide is degraded into small peptide fragments in the cytoplasm. Some of these
30 small peptides translocate into a pre-Golgi compartment and interact with class I heavy
chains to facilitate proper folding and association with the subunit $\beta 2$ microglobulin. The
peptide-MHC class I complex is then routed to the cell surface for expression and
potential recognition by specific T cells. Investigations of the crystal structure of the
human MHC class I molecule HLA-A2.1 indicate that a peptide binding groove is created

SUBSTITUTE SHEET (RULE 26)

by the folding of the $\alpha 1$ and $\alpha 2$ domains of the class I heavy chain (Bjorkman *et al.*, (1987) *Nature* 329:506. Falk *et al.*, (1991) *Nature* 351:290 have developed an approach to characterize naturally processed peptides bound to class I molecules. Other investigators have successfully achieved direct amino acid sequencing of the more abundant antigenic peptides in various HPLC fractions by conventional automated sequencing of peptides eluted from class I molecules (Jardetzky, *et al.* (1991) *Nature* 353:326 and mass spectrometry Hunt, *et al.*, *Science* 225:1261 (1992). A review of the characterization of naturally processed peptides in MHC Class I is found in Rötzschke and Falk (1991) *Immunol. Today* 12:447.

Target T cells recognizing antigenic peptides can be induced to differentiate and proliferate in response to antigen presenting cells bearing antigenic peptides in the context of MHC class I and class II complexes. There are differences in the antigenic peptides bound to MHC class I and class II molecules, but the two classes of bound peptides share common epitopes within the same protein which enable a T cell activated by an antigen presenting cell to recognize a corresponding MHC class I epitope. MHC class I molecules on target cells typically bind 9 amino acid antigenic peptides, while corresponding MHC class II-peptide complexes have greater heterogeneity in the size of the bound antigenic peptide.

The generation of target T cells with a desired specificity has been limited by the ability of investigators to discover appropriate peptides for loading onto MHC molecules, and by investigator's ability to load peptide antigens onto antigen presenting cells used to induce proliferation of the T cells. In the past, investigators have generated antigen presenting cells by stripping the antigenic peptides normally found on antigen presenting cells by chemical or thermal techniques, followed by a reloading of the cells with a desired antigenic peptide. This approach has had limited success, due to inefficiencies in antigen presenting cell peptide loading, and due to the limited length of time that the loaded antigenic peptides remain loaded on the antigen presenting cells. In addition, only a single peptide fragment of a protein is loaded onto the surface of the antigen presenting cell using typical methods; thus, peptides important for activation of T cells against a target cell can be overlooked. The present invention overcomes these and other problems.

SUMMARY OF THE INVENTION

The invention provides new methods of making recombinant antigen presenting dendritic cells (DCs), which have been very difficult to transduce using existing methods. These new methods are applicable to the transduction of DCs with any recombinant nucleic acid. Also provided are new ways of expressing antigenic peptides on MHC molecules on the surface of the dendritic cells. It was surprisingly discovered that these expressed antigenic peptides are processed and displayed on the surface of the dendritic cells in the context of class I and class II MHC. These recombinant cells expressing antigenic peptides were found to be competent to activate T-cells against target cells expressing selected antigens *in vivo*. This provides powerful new treatments for cancers and cellular infections, as well as a variety of diagnostic and cell screening assays.

Naturally occurring dendritic cells are antigen presenting cells which activate T cell proliferation against target cells. Target cells express antigenic peptides in the context of MHC class I molecules on the surface of the target cell. Dendritic cells express related antigenic peptides on class I and class II MHC molecules. In a preferred use of the invention, dendritic cells are transformed with a nucleic acid encoding a heterologous protein which has a peptide subsequence corresponding to an antigenic peptide expressed on the surface of a target cell (on an MHC class I receptor). Preferably, a full-length protein is expressed, and several processed subsequences subsequently presented by the dendritic cell.

Surprisingly, heterologous proteins are expressed in the dendritic cell, processed into fragments, and expressed on the surface of the dendritic cell in the context of MHC class I and II molecules, making the dendritic cells capable of activating T cell proliferation against a target cell expressing the corresponding antigen. It is further demonstrated herein that T-cells activated by the dendritic cells of the invention by the methods of the invention are effective against established tumors and metastasis, *in vivo*. Thus, the present invention provides powerful new anti-cancer therapies based upon immunizing a patient with a recombinant dendritic cell, and/or T cell activated by a recombinant dendritic cell.

The new methods of transforming dendritic cells and expressing antigenic peptides on the surface of the cell to make the dendritic cell competent for T cell

activation, provide significant advantages over prior art methods of loading peptides onto dendritic cells, including broader antigen expression and more efficient MHC class I and class II peptide loading, and the ability to expand the population of desired DCs, *e.g.*, in culture. The invention has diagnostic, therapeutic and drug discovery assay uses.

5 DCs can be transduced with essentially any nucleic acid using the techniques provided. In one preferred embodiment, nucleic acids encoding cytokines (*e.g.*, GM-CSF, an interleukin (IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, *etc.*), or cell receptor ligands (*e.g.*, transferrin, c-kit, viral receptor ligands, cytokine receptors, and the like) are transduced into stem cells to
10 produce recombinant DC.

In one class of embodiments, the invention provides methods of transducing dendritic cells with selected nucleic acids. In the methods, a hematopoietic stem cell, *e.g.*, a human CD34⁺ stem cell, is transduced with a selected nucleic acid, and the stem cell is then differentiated into a dendritic cell. Typically, the stem cell is differentiated *in*
15 *vitro* using appropriate cytokines. For instance, mouse stem cells are differentiated into dendritic cells by incubating the stem cells in culture with murine GM-CSF. Typically, the concentration of GM-CSF in culture is at least about .2ng/ml, and preferably at least about 1 ng/ml. Often the range will be between about 20 ng/ml and 200 ng/ml. In many preferred embodiments, the dose will be about 100 ng/ml. When human cells are
20 transduced, human GM-CSF is used in similar ranges, and TNF- α is also added to facilitate differentiation. TNF- α is also typically added in about the same ranges. Optionally, SCF is added in similar dose ranges to make human DCs. Optionally, IL-4 is added in similar ranges, particularly for making murine DCs.

Ordinarily, the differentiation process is performed *in vitro*. Other
25 cytokines such as IL-4 are optionally added to facilitate cell culture and cell differentiation. In addition, lipofectamine, or a similar transduction facilitating agent, is optionally added for improving gene transfer to cultures for producing recombinant DCs.

One preferred way of transducing a hematopoietic stem cell with a selected nucleic acid is to incubate the stem cell with a retroviral vector comprising the selected
30 nucleic acid. Preferred vectors for stem cells include murine leukemia virus vectors. For human stem cells, murine leukemia virus vectors expressing Gibbon Ape leukemia virus

envelopes are also preferred. For transducing murine stem cells, ecotropic envelopes are preferred.

Thus, the invention also provides recombinant dendritic cells with expression cassettes. The expression cassettes express proteins (or peptide fragments thereof) which are processed into antigenic peptides expressed on the surface of the dendritic MHC class I and II surface receptors. The expression cassettes typically comprise a strong promoter such as a t-RNA pol III promoter, or a pol II promoter with strong constitutive expression. One preferred pol II promoter is the retroviral murine leukemia virus LTR promoter. Example antigenic proteins expressed by the expression cassette include HER-2, MART-1, gp-100 and CEA, tyrosinase, MAGE, trp-1 and PSA.

In another preferred class of embodiments, the invention provides methods for activating T cells. In the methods, the T cell is contacted with a recombinant dendritic cell expressing a recombinant protein which is processed into antigenic peptides on the surface of the dendritic cell. The T cell is optionally contacted with the dendritic cell *in vitro* or *in vivo*. Thus, in one preferred embodiment, T cells are isolated from a mammal and incubated with recombinant dendritic cells *in vitro*. After incubation, the T cells can be used in assays, or re-introduced into the mammal to target and kill cells with antigenic peptides (bound to class I MHC molecules) corresponding to the peptides expressed on the surface of the dendritic cell. In another preferred embodiment, the recombinant dendritic cell is introduced into a mammal to activate the T cell *in vivo*. Preferred target cells are those expressing antigenic peptides in the context of MHC class I molecules, including cancer cells (*e.g.*, prostate, colon, melanoma, and breast cancer cells), virally infected cells such as cells infected with an HIV, hepatitis or herpes virus, and parasitized cells including cells with intracellular bacterial infections and cells infected with parasites such as stages of *P. falciparum* (the primary causative agent for malaria).

The invention provides commercially valuable drug and cell assays. For instance, methods for detecting T cell mediated anti-cancer cell activity of a protein or peptide are provided. In the assays, a dendritic cell is transformed with a recombinant expression cassette encoding a heterologous protein or fragment thereof (*e.g.*, an antigenic peptide) by the methods described herein. The T cell is contacted with the dendritic cell *in vivo* or *in vitro*, thereby activating the T cell against cells expressing a

peptide antigen (on a MHC class I molecule) corresponding to an antigen expressed on the surface of the dendritic cell. To test whether the T cell has anti-cancer cell activity, a selected cancer cell (for instance a breast cancer, melanoma, prostate cancer, or colon cancer cell) is incubated with the T-cell (*in vitro* or *in vivo*) and inhibition of cancer cell replication, or T-cell mediated cancer cell lysis, or specific cytokine release (*e.g.*, GM-CSF, IFN- γ or TNF- α) is observed. The assay is optionally performed *in vitro*, or optionally *in vivo*. By providing a way of discriminating proteins which can be targeted on cancer cells, the invention provides a commercially valuable assay. The same strategy can be applied to detect antigens or virally or parasitically infected cells by substitution of these cells for the cancer cells in the assay.

The activated T cells of the invention are generally cytotoxic against cells expressing antigenic peptides in the context of MHC which correspond to antigens expressed on antigen presenting cells. Thus, the invention provides a method for making T cells cytotoxic to selected target cells. In the methods, T cells are activated by contact with the recombinant dendritic cells of the invention, *in vitro* or *in vivo*.

The transformation of dendritic cells with target proteins changes the antigenic repertoire of the dendritic cell by causing processed peptide fragments to be expressed on the MHC molecules of the dendritic cell. Unlike untransformed dendritic cells, the recombinant transformed dendritic cells have processed peptide fragments derived from the target protein expressed on the surface of the dendritic cell.

In one embodiment, diagnostic assays are provided. These assays are used to determine whether a cell population (*e.g.*, a blood or cell sample from a patient) express a selected antigen. In the assays, recombinant dendritic cells expressing the selected antigen are used to activate T-cells against the antigen. The cell population is then exposed to the activated T-cells, and lysis of the cells is monitored (*e.g.*, by Trypan blue exclusion). If the observed lysis is higher than an appropriate control, the population of cells comprises the antigen. This can be used, *e.g.*, to assess whether tumor cells express a particular antigen. In another class of diagnostic assays, the invention provides a way of monitoring precursor frequency and/or T-cell reactivity by exposure to recombinant DCs. This is an indicator of the effect of immunization with DCs.

DESCRIPTION OF THE DRAWING

Figure 1 shows the results of a mixed leukocyte reaction using dendritic cells to activate T cells, with Splenocytes as a control. The dendritic cells were generated with varying amounts of murine GM-CSF.

5 Figure 2 shows the results of a mixed lymphocyte reaction using dendritic cells to activate T cells, with Splenocytes as a control.

Figure 3 shows the sequence of a MART-1 nucleic acid.

Figure 4 shows an allogenic MLR with dendritic cells and PBMC.

10 Figure 5 shows an allogenic MLR with dendritic cells, MART transformed dendritic cells and PBMC.

Figure 6 is a bar graph showing that mice treated with β gal-transduced DC exhibited a significant reduction in pulmonary metastases compared to the control group.

15 Figure 7 shows Lysis of tumor and peptide-pulsed cells by lymphocytes stimulated with MART-transduced DCs. Autologous quiescent lymphocytes were stimulated with MART-transduced DCs (●) or SAM-transduced DCs (○). After two restimulations, the lymphocytes, or the positive control 1235 TIL (■), were tested for their ability to lyse various cells. Results are plotted as the mean percentage of lysis \pm SEM.

DEFINITIONS

20 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton *et al.* (1994) *Dictionary of Microbiology and Molecular Biology*, second edition, John Wiley and Sons (New York), and Hale and Marham (1991) *The Harper Collins Dictionary of Biology* Harper Perennial, NY provide
25 one of skill with a general reference for many of the terms used in this invention. Paul (1993) *Fundamental Immunology, Third Edition* Raven Press, New York, NY and the references cited therein provide one of skill with a general overview of the ordinary meaning of many of the immunologically related terms herein. Although any methods and materials similar or equivalent to those described herein can be used in the practice
30 or testing of the present invention, preferred methods and materials are described. For purposes of the present invention, the following terms are defined below.

A "dendritic cell" (DC) is an antigen presenting cell (APC) which can be derived from a hematopoietic stem cell. DC can be obtained from many lymphoid and non lymphoid tissues, as well as peripheral blood and bone marrow. Hematopoietic stem cells such as CD34⁺ cells in humans can be artificially differentiated into DC *in vitro*.

- 5 The dendritic cell has a characteristic morphology with thin sheets (lamellipodia) extending from the dendritic cell body in several directions. Several phenotypic criteria are also typical, but can vary depending on the source of the dendritic cell. These include high levels of MHC molecules and costimulatory molecules (*e.g.*, B7-1 and B7-2), a lack of markers specific for granulocytes, NK cells, B cells, and T cells. In the
10 mouse, some (but not all) dendritic cells express 33D1 (DC from spleen and Peyer's patch, but not skin or thymic medulla), NLDC145 (DC in skin and T-dependent regions of several lymphoid organs and CD11C (Cd11c also reacts with macrophage). Dendritic cells are able to initiate primary T cell responses *in vitro* and *in vivo*. These responses are antigen specific. Dendritic cells direct a strong mixed leukocyte reaction (MLR)
15 compared to peripheral blood leukocytes, splenocytes, B cells and monocytes.

- A "target cell" or a "T cell targeted cell" is a cell which expresses an antigenic peptide on a MHC class I molecule on the surface of the cell. T cells recognize the antigenic peptides bound to the MHC molecule and kill the target cell, either by cell lysis, or by recruiting other immune cells to the site of the target cell by releasing
20 cytokines. The T cells which recognize the antigenic peptide-MHC molecule are induced to proliferate in response to antigen presenting cells (*e.g.*, dendritic cells) which express corresponding antigenic peptides on their cell-surface MHC molecules.

- A "target protein" is a protein which comprises antigenic peptide subsequences. These subsequences are expressed on target cells in the context of MHC
25 molecules. T cells recognize epitopes formed by the binding of an MHC molecule to these peptide subsequences and typically lyse the cell, or recruit other immune cells (*e.g.*, macrophage) to the site of the target cell, thereby killing the target cell.

- An "immunogenic peptide" or "antigenic peptide" is a peptide which will bind an MHC allele to form an epitope recognized by a T cell, thereby inducing a CTL
30 response upon presentation to the T cell. Thus, antigenic peptides are capable of binding to an appropriate MHC molecule and inducing a cytotoxic T cell response, *e.g.*, cell lysis or specific cytokine release against the target cell which binds or expresses the antigen.

The antigenic peptide can be bound in the context of a class I or class II MHC molecule, on an antigen presenting cell, or on a target cell.

“Changing the antigenic repertoire” of an antigen presenting cell such as a dendritic cell refers to the processing and expression of a heterologous protein into
5 heterologous antigenic peptides on the surface of the antigen presenting dendritic cell (*i.e.*, due to transformation of the antigen presenting cell with a recombinant expression cassette encoding an antigenic protein). The antigen presenting cell expresses antigenic processed fragments of the heterologous protein on the surface of the cell in the context of class I and class II MHC molecules. The expression of these heterologous processed
10 fragments makes the antigen presenting cell competent to induce quiescent T cells which recognize the MHC-antigenic peptide epitope to proliferate against target cells which have epitopes derived from the heterologous protein (*i.e.*, antigenic peptides expressed on MHC class I molecules on the cell). These T cells then lyse the target cells, or recruit other immune cells to the site of the target cell (*e.g.*, macrophage) which kill the target
15 cells.

A “hematopoietic stem cell” is a pluripotent cell found, *e.g.*, in bone marrow or peripheral blood which can be differentiated into a given cell type by incubation *in vitro* or *in vivo* with appropriate cytokines. For instance, hematopoietic stem cells from mouse bone marrow can be differentiated into dendritic cells by
20 incubation with murine GM-CSF, and, optionally, other cytokines as shown herein. One well-characterized class of hematopoietic stem cells from humans is a class of cells which are CD34⁺, which can be differentiated into dendritic cells by incubation with human GM-CSF and TNF- α .

A cell is “transduced” with a selected nucleic acid when the nucleic acid is
25 translocated into the cell. A cell is “stably transduced” with a selected nucleic acid when the selected nucleic acid is replicated and passed on to progeny cells. A cell is “transformed” with a selected nucleic acid when the selected nucleic acid is integrated into the cell’s genome.

CD34⁺ cells express CD34 receptor molecules on the surface of the cell.

30 A cell is “negative” for a class of MHC molecules when the level of expression of the class of MHC molecules on the surface of the cell is less than 10% the level on a differentiated dendritic cell. Alternatively, a cell is “negative” for a class of

MHC molecules when the cell cannot be isolated from a population of cells by FACS using the MHC molecule as a marker, or when an isotype matched antibody control binds to the cell with the same intensity (\pm about 5%) as an MHC antibody.

A "cell receptor ligand" is a biological molecule which binds to a cell
5 receptor (which is optionally an extracellular receptor or an intracellular receptor), thereby activating the receptor.

The terms "isolated" or "biologically pure" refer to material which is substantially or essentially free from components which normally accompany it as found in its naturally occurring environment. The isolated material optionally comprises
10 material not found with the material in its natural environment.

The term "nucleic acid" refers to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, encompasses known analogues of natural nucleotides that hybridize to nucleic acids in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a
15 particular nucleic acid sequence optionally includes the complementary sequence thereof. A nucleic acid "encodes" another nucleic acid where it is the same as the specified nucleic acid, or complementary to the specified nucleic acid.

The term "operably linked" refers to functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor
20 binding sites) and a second nucleic acid sequence (such as a nucleic acid for a heterologous protein), wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

"Optimal differentiation" of a population of stem cells into a population of dendritic cells in the context of a titration experiment for a particular cytokine refers to
25 achieving the highest percentage of dendritic cells in the population after incubation with the cytokine. Typically, titrations include systematically varying cytokine concentration and/or incubation time and comparing the results of the different concentrations or incubations.

An "expression vector" includes a recombinant expression cassette which
30 has a nucleic acid which encodes a polypeptide (*i.e.*, a protein) that can be transcribed and translated by a cell. A "recombinant expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements

which permit transcription of a particular nucleic acid in a target cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of the expression vector includes a nucleic acid to be transcribed, and a promoter. In some embodiments, the expression cassette also includes, *e.g.*, an origin of replication, and/or chromosome integration elements such as retroviral LTRs. A "promoter" is an array of nucleic acid control sequences which direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. The promoter also optionally includes distal enhancer or repressor elements which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter which is active under most environmental conditions and states of development or cell differentiation. An "inducible" promoter responds to an extracellular stimulus.

The term "recombinant" when used with reference to a cell indicates that the cell replicates or expresses a nucleic acid, or expresses a peptide or protein encoded by a nucleic acid whose origin is exogenous to the cell. Recombinant cells can express genes that are not found within the native (non-recombinant) form of the cell. Recombinant cells can also express genes found in the native form of the cell wherein the genes are re-introduced into the cell by artificial means, for example under the control of a heterologous promoter.

The term "heterologous" when used with reference to a nucleic acid indicates that the nucleic acid comprises two or more subsequences which are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences derived from unrelated genes arranged to make a new functional nucleic acid. For example, in one embodiment, the nucleic acid has a promoter from one gene arranged to direct the expression of a coding sequence from a different gene. When used with reference to a protein, the term "heterologous" means that the protein is expressed in a cell or location where it is not ordinarily expressed in nature, such as in a recombinant dendritic cell which encodes the protein in an expression cassette.

The term "subsequence" in the context of a particular nucleic acid or polypeptide sequence refers to a region of the nucleic acid or polypeptide equal to or smaller than the particular nucleic acid or polypeptide.

A "primary" stem cell is a stem cell isolated from a patient. A "primary dendritic cell" is a dendritic cell taken from a patient, or derived by differentiation of a stem cell taken from a patient. A primary dendritic cell in an established cell culture which has undergone many serial passages in culture is not a primary dendritic cell, but may be referred to as an established dendritic cell. A "primary cultured dendritic cell" is a dendritic cell differentiated from a culture of primary stem cells.

DETAILED DISCUSSION OF THE INVENTION

Dendritic cells (DC) are highly potent antigen presenting cells that are capable of activating quiescent T-cells, and stimulate effective anti-tumor immune responses. Dendritic cells have been effective against established tumors. Dendritic cells have several advantages over other forms of anti-tumor immunization, such as recombinant viral vaccines, in that the immunization method is entirely autologous, and therefore no problems with pre-existing neutralizing antibodies are expected, even with repeated dosing. In addition, dendritic cell immunizations can be used in combination with other methods of immunization.

The ability to constitutively express tumor antigen genes in dendritic cells, as taught herein, is a powerful method to uncover new tumor antigens *in vitro* and to actively immunize against cells expressing the antigens *in vivo* and *ex vivo*. Methods allowing efficient gene transfer into primary dendritic cells are useful for several reasons.

First, entire antigen genes can be introduced, allowing presentation of the entire protein by the dendritic cell. Second, by permanently and stably expressing the antigen gene in dendritic cells, the antigen is constitutively expressed, compared to only transient expression with more traditional peptide pulsing. Third, introduction of the entire protein allows the presentation of multiple, and even undefined, but important, epitopes. In addition, both class I and class II epitopes can be presented. Fourth, introduction of candidate tumor antigen genes or cDNA libraries allows the identification of novel tumor antigens against common cancers. Fifth, cytokine genes, such as GM-CSF can be introduced into dendritic cells, to potentially enhance their survival, immunogenicity or therapeutic effect. Sixth, Stimulatory ligands, such as CD40L, can be

introduced in dendritic cells, to enhance their survival, immunogenicity or therapeutic effects. Seventh, transcription factors and other molecules important for dendritic cell differentiation are introduced to study the basic science of primary dendritic cell development.

5 The invention provides new methods of transforming antigen presenting dendritic cells. In a preferred use of the invention, the dendritic cells are transformed with a nucleic acid encoding a protein which has peptide subsequences expressed on the surface of target cells in the context of MHC class I molecules. The protein is expressed in the dendritic cell, processed into fragments, and expressed on the surface of the
10 dendritic cell in the context of the MHC class I and class II receptors found on the surface of dendritic cells. These dendritic cells are capable of activating T cell proliferation of T cells cytotoxic to a target cell.

Typically, the dendritic cells of the invention are transformed by transforming a hematopoietic stem cell with a selected nucleic acid, followed by
15 differentiation of the stem cell into the dendritic cell. A primary advantage of this strategy is that many known methods of transducing cells require the cell to be actively dividing for stable integration of the selected nucleic acid into the cellular genome. For instance, many retroviral gene therapy vectors can only transform actively dividing cells. It is now discovered that these methods of transducing and transforming cells do not work
20 with dendritic cells. Thus, stem cells are transformed with selected nucleic acids in the methods of the invention, and then differentiated into dendritic cells which then stably express the selected nucleic acid.

The new methods of transforming dendritic cells and expressing antigenic peptides on the surface of the cell to make the dendritic cell competent for T cell
25 activation provides significant advantages over prior art methods of loading peptides onto dendritic cells, including broader antigen expression and more efficient MHC class I and class II peptide loading. Peptide loading methods are of limited efficiency, and ordinarily only a single peptide is loaded. In contrast, it is shown herein that endogenous expression of a protein provides for efficient loading of MHC class I and class II
30 molecules, and that a whole range of peptides derived from a selected target protein are presented on the surface of the dendritic cell for antigen presentation. These fundamental discoveries provide diagnostic, therapeutic and assay uses.

Epitopes from a variety of pathogens on a number of potential target cells are known to mediate T cell cytotoxicity of the target cells, and it is expected that one of skill is thoroughly familiar with the identity of many such antigens. T cells recognizing such epitopes are stimulated to proliferate in response to antigen presenting cells such as dendritic cells. Examples of MHC class I bound antigens include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (*e.g.*, MAGE-1, MART-1 and gp 100), Colon cancer antigens (*e.g.*, CEA), breast cancer antigens (*e.g.*, HER-2) human immunodeficiency virus (HIV) antigens, herpes virus antigens, hepatitis (*e.g.*, A, B, or C) tyrosinase, trp-1, Malarial antigens, or human papilloma virus (HPV) antigens. A nucleic acid encoding MART-1 is provided in Figure 3.

DC can be transduced with essentially any nucleic acid using the techniques provided. In one preferred embodiment, nucleic acids encoding cytokines (*e.g.*, GM-CSF, an interleukin (IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, *etc.*), or cell receptor ligands (*e.g.*, transferrin, c-kit, CD40 ligand, viral receptor ligands, cytokine receptors, and the like) are transduced into stem cells to produce recombinant DC expressing the encoded protein or peptide. Cytokines and cytokine receptors, such as interleukins and interleukin receptors, c kit and the c kit receptor (*see*, Schwartzenberger *et al.* (1996) *Blood* 87: 472-478), as well as cell ligands (*e.g.*, CD40), chemokines, as well as recombinant antibodies and cell surface molecules, and the like are known, and commercially available. Cytokines include, *e.g.*, IL-1, IL-2, IL-4, TNF α , IL-6, interferons alpha, beta and gamma, and GM/CSF. *See also*, Cao *et al.* (1995) *Cancer Res Clin Oncol* 121(12):721-8; Dalglish, (1994) *Gene Ther* 1(2):83-7; Suminami *et al.* (1995) *J Immunother Emphasis Tumor Immunol* 17(4):238-48; Abe *et al.* (1995) *J Cancer Res Clin Oncol* 121(9-10):587-92; Garbe and Krasagakis, (1993) *Invest Dermatol* 100(2 Suppl):239S-244S. For a review of the chemokine family, *see, e.g.*, Lodi *et al.* (1994) *Science* 263: 1762-1767; Gronenborn and Clore (1991) *Protein Engineering* 4: 263-269; Miller and Kranger (1992) *Proc. Nat'l Acad. Sci. USA* 89: 2950-2954; Matsushima and Oppenheim (1989) *Cytokine* 1: 2-13; Stoeckle and Baker (1990) *New Biol.* 2: 313-323; Oppenheim *et al.* (1991) *Ann. Rev. Immunol.* 9: 617-648; Schall (1991) *Cytokine* 3: 165-183; and *The Cytokine Handbook* Academic Press, NY.

Nucleic acids encoding cytokines, growth factors, cell receptor ligands, *etc.*, for increasing the survival, differentiation, selection (*e.g.*, by transducing the cells with a selectable marker such as an antibiotic resistance gene), immunogenicity, or therapeutic effect of the cells are all preferably placed into a recombinant expression cassette and used to transduce DCs. DCs are optionally made which express a peptide on an MHC molecule, and simultaneously express a cytokine and/or other gene.

In preferred embodiments, primary stem cells are differentiated into dendritic cells. One of skill will appreciate that many therapeutic applications are improved by administering autologous cells to a patient, *i.e.*, cells which were originally isolated from the patient, or which are derived from a patient by culturing isolated cells. These autologous cells are less likely to cause immune complications upon reintroduction into the patient. Moreover, primary isolates of dendritic cells are the most refractory to transduction by heterologous nucleic acids. Because the invention provides transformed dendritic cells derived from primary cell culture of stem cells, the invention overcomes this significant problem in the art.

Isolating Stem Cells

Stem cells are isolated for transduction and differentiation into dendritic cells in the methods of the invention. Many ways of isolating stem cells are known.

In mice, bone marrow cells are isolated, *e.g.*, by sacrificing the mouse and cutting the leg bones with a pair of scissors. Stem cells are isolated from bone marrow cells by panning the bone marrow cells with antibodies which bind unwanted cells, such as CD4⁺ and CD8⁺ (T cells), CD45⁺ (panB cells), GR-1 (granulocytes), and Ia^d (differentiated antigen presenting cells). *For an example of this protocol see, Inaba et al. (1992) J. Exp. Med. 176, 1693-1702.*

Human CD34⁺ cells can be obtained from a variety of sources, including cord blood, bone marrow, and mobilized peripheral blood. Purification of CD34⁺ cells can be accomplished by antibody affinity procedures. An affinity column isolation procedure for isolating CD34⁺ cells is described by Ho *et al.* (1995) *Stem Cells* 13 (suppl. 3): 100-105. *See also, Brenner (1993) Journal of Hematotherapy* 2: 7-17. Yu *et al.* (1995) *PNAS* 92: 699-703 describe a method of transducing CD34⁺ cells from human fetal cord blood using retroviral vectors.

In humans, bone marrow aspirations from iliac crests are optionally performed *e.g.*, under general anesthesia in the operating room. The bone marrow aspiration is approximately 1,000 ml in quantity and is collected from the posterior iliac bones and crests. If the total number of cells collected is $< \text{about } 2 \times 10^8/\text{kg}$, a second aspiration is optionally performed, *e.g.*, using the sternum and/or anterior iliac crests in addition to posterior crests. During the operation, two units of irradiated packed red cells are administered to replace the volume of marrow taken by the aspiration. Human hematopoietic progenitor and stem cells are characterized by the presence of a CD34 surface membrane antigen. This antigen is often used for purification. After the bone marrow is harvested, the mononuclear cells are separated from the other components by means of ficol gradient centrifugation. This is performed by a semi-automated method using a cell separator (*e.g.*, a Baxter Fenwal CS3000+ or Terumo machine). The light density cells, composed mostly of mononuclear cells are collected and the cells are incubated in plastic flasks at 37°C for 1.5 hours. The adherent cells (monocytes, macrophages and B-Cells) are discarded. The non-adherent cells are then collected and incubated with a monoclonal anti-CD34 antibody (*e.g.*, the murine antibody 9C5) at 4°C for 30 minutes with gentle rotation. The final concentration for the anti-CD34 antibody is 10 µg/ml. After two washes, paramagnetic microspheres (Dyna Beads, supplied by Baxter Immunotherapy Group, Santa Ana, California) coated with sheep antimouse IgG (Fc) antibody are added to the cell suspension at a ratio of 2 cells/bead. After a further incubation period of 30 minutes at 4°C, the rosetted cells with magnetic beads are collected with a magnet. Chymopapain (supplied by Baxter Immunotherapy Group, Santa Ana, California) at a final concentration of 200 U/ml is added to release the beads from the CD34+ cells. Alternatively, and preferably, an affinity column isolation procedure can be used which binds to CD34, or to antibodies bound to CD34 (*see*, the examples below).

In another highly preferred embodiment, CD34+ cells are isolated from peripheral blood leukapheresis after G-CSF mobilization as described more fully in the examples below.

30 **Transducing and Culturing Stem Cells**

Several ways of transforming stem cells are known, including calcium phosphate precipitation, fusion of the recipient cells with bacterial protoplasts containing

the DNA, treatment of the recipient cells with liposomes containing the DNA, DEAE dextran, receptor-mediated endocytosis, electroporation, micro-injection of the DNA directly into the cells, incubating viral vectors containing selected nucleic acids which encode polypeptides of interest with cells within the host range of the vector, calcium phosphate transfection, and many other techniques known to those of skill. See, *e.g.*,
5 *Methods in Enzymology*, vol. 185, Academic Press, Inc., San Diego, CA (D.V. Goeddel, ed.) (1990) or M. Krieger, *Gene Transfer and Expression -- A Laboratory Manual*, Stockton Press, New York, NY, (1990) and the references cited therein, as well as Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology*
10 volume 152 Academic Press, Inc., San Diego, CA (Berger); Sambrook *et al.* (1989) *Molecular Cloning - A Laboratory Manual* (2nd ed.) Vol. 1-3; and *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1994 Supplement) (Ausubel). Product information from manufacturers of biological reagents and
15 experimental equipment also provide information useful in known biological methods. Such manufacturers include the SIGMA chemical company (Saint Louis, MO), R&D systems (Minneapolis, MN), Pharmacia LKB Biotechnology (Piscataway, NJ), CLONTECH Laboratories, Inc. (Palo Alto, CA), Chem Genes Corp., Aldrich Chemical Company (Milwaukee, WI), Glen Research, Inc., GIBCO BRL Life Technologies, Inc.
20 (Gaithersburg, MD), Fluka Chemica-Biochemika Analytika (Fluka Chemie AG, Buchs, Switzerland), Invitrogen, San Diego, CA, and Applied Biosystems (Foster City, CA), as well as many other commercial sources known to one of skill.

Several approaches for introducing functional new genetic material into cells *in vivo* and *ex vivo* have been used. These include liposome based gene delivery
25 (Debs and Zhu (1993) WO 93/24640; Mannino and Gould-Fogerite (1988) *Biotechniques* 6(7): 682-691; Rose U.S. Pat No. 5,279,833; Brigham (1991) WO 91/06309; and Felgner *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84: 7413-7414) and replication-defective retroviral vectors harboring a therapeutic polynucleotide sequence as part of the retroviral genome (*see, e.g.*, Miller *et al.* (1990) *Mol. Cell. Biol.* 10:4239 (1990); Kolberg (1992)
30 *J. NIH Res.* 4:43, and Cornetta *et al.* *Hum. Gene Ther.* 2:215 (1991)). Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), ecotropic retroviruses, simian immuno deficiency virus (SIV),

human immuno deficiency virus (HIV), and combinations thereof. *See, e.g.,* Buchscher *et al.* (1992) *J. Virol.* 66(5) 2731-2739; Johann *et al.* (1992) *J. Virol.* 66 (5):1635-1640 (1992); Sommerfelt *et al.*, (1990) *Virol.* 176:58-59; Wilson *et al.* (1989) *J. Virol.* 63:2374-2378; Miller *et al.*, *J. Virol.* 65:2220-2224 (1991), and Rosenberg and Fauci (1993) in *Fundamental Immunology, Third Edition* Paul (ed) Raven Press, Ltd., New York and the references therein, and Yu *et al.*, *Gene Therapy* (1994) *supra*.

Retroviral Vectors

The preferred method of transforming stem cells is to incubate the cells with a viral vector, within the host range of the virus. Many such viral vectors are known, including retroviral vectors based on, *e.g.*, HIV viruses, SIV viruses, murine retroviruses, gibbon ape leukemia virus and other viruses such as adeno associated viruses (AAVs) and adeno viruses.

Murine retroviral vectors are known in the art. The majority of the approved gene transfer trials in the United States rely on replication-defective retroviral vectors derived from murine retroviruses such as murine moloney retrovirus (referred to alternately as MoLv MoMuLv or MuLV in the art). *See* Miller *et al.* (1990) *Mol. Cell. Biol.* 10:4239; Kolberg R (1992) *J. NIH Res.* 4:43, and Cornetta *et al.* (1991) *Hum. Gene Ther.* 2:215. The major advantage of murine retroviral vectors for gene therapy are the high efficiency of gene transfer into certain types of replicating cells, the precise integration of the transferred genes into cellular DNA, and the lack of further spread of the sequences after gene transfer.

Murine vectors comprising Gibbon Ape Leukemia Virus envelopes are more broadly infective than Murine retroviruses such as Murine leukemia virus, and can be used to transduce many mammalian stem cells, including human stem cells. Gibbon Ape Leukemia Virus (GaLV) infects cells using the GaLV receptor, which is found on many cell types in many species. *See, Johann et al., J. Virol.* 66:1635-1640 (1992). GaLV can infect many mammalian species with the notable exception of mouse cells. The same receptor is used by simian sarcoma associated virus (SSAV), a strain of GaLV. Sommerfelt *et al.*, *Virol.* 176:58-59 (1990).

The construction of hybrid virions having GaLV envelope proteins has been demonstrated. For instance, Wilson *et al.*, *J. Virol.* 63:2374-2378 (1989), describe preparation of infectious hybrid virions with GaLV and human T-cell leukemia virus

retroviral *env* glycoproteins and the *gag* and *pol* proteins of the Moloney murine leukemia virus (MoMLV). In addition, Miller et al., *J. Virol.* 65:2220-2224 (1991), describe construction of hybrid packaging cell lines that express GaLV envelope and MoMLV *gag-pol* proteins. Any of these vectors and methods of making retroviral clones can be applied to the present invention. GaLV Retroviral packaging cell lines can be used to provide infectious replication-defective hybrid virions for use in gene transfer in humans, hamsters, cows, cats, dogs, monkeys, chimpanzees, macaques, primates, and other species whose cells have host cell receptors for GaLV envelope proteins.

HIV-based retroviral vectors are made competent to transduce CD34⁺ cells by pseudotyping the vector. This is done, for example, by transducing the packaging cell line used to package the vector with a nucleic acid which encodes the vesicular stomatitis virus (VSV) envelope protein, which is then expressed on the surface of the HIV vector. VSV infects CD34⁺ cells, and pseudotype vectors expressing VSV envelope proteins are competent to transduce these cells (Naldini et al. (1996) *Science* 272:263).

Other HIV-based vector systems have been used. See, Akkina et al. (1996) *J Virol* 70:2581; Poznansky et al. (1991) *J Virol* 65:532; Parolin et al. (1994) *Journal of Virology* 68:3888; Richardson et al. (1995) *Journal of General Virology* 76:691; Buchschacher et al. (1992) *Journal of Virology* 66:2731; and Marlink et al. (1994) *Science* 265:1587.

A number of standard techniques are used to improve safety of retroviral vectors. For instance, a defective retroviral genome is introduced into the packaging cell separately from the genes encoding the core and envelope components. In this way, recombination between the genome and the core and envelope genes, which would lead to the packaging of complete viral genomes, is extremely unlikely. The resulting virions typically do not comprise the *gag*, *pol*, and *env* genes and are thus replication-defective. Homologous recombination, however, between the inserts can lead to the production of infectious virions. Accordingly, the packaging cells are produced by introducing the *gag*, *pol*, and *env* genes on at least two separate plasmids. This scheme effectively prevents homologous recombination leading to reconstruction of infectious virus because the probability of multiple, independent homologous recombination events occurring is extremely low.

Retroviral vectors can also be designed to prevent synthesis of viral proteins by the integrated defective genome. For instance, if a portion of the *gag* gene is included to increase packaging efficiency, a stop codon can be introduced into the gene to prevent synthesis of *gag* proteins. See, Miller et al., *Biotechniques* 7:982-988 (1989).

5 In addition, the cells used to make packaging cells do not typically possess a cell receptor for the relevant vector, and are thus not infectable by the vector. Thus, for instance, retroviral vector virions having the GaLV envelope cannot reinfect the packaging cells; thus, vector spread in the packaging cells is greatly reduced. Suitable packaging cells also have limited or no endogenous viral sequences. Cell lines for this purpose include the *Mus dunni* tail fibroblast cell line. This strategy decreases the potential for generation of recombinant vectors, which are often transmitted with higher efficiency than the parental vector.

Alternatively, genes are expressed in dendritic cells using recombinant adenoviral vectors, AAV vectors, pox viral vectors (B. Moss, "Poxvirus Expression Vectors", *Current Topics in Microbiology and Immunology*, Vol 158; 25-38, 1992) including vaccinia, fowl pox, and canary pox, recombinant influenza viral vectors (Garcia-Sastre, A., and P. Palese, "Influenza Virus Vectors", *Biologicals*, 23:171-178, 1995), or non-viral gene delivery techniques (F. Ledley, "Non-viral gene therapy", *Current Opinion in Biotechnology*, 5:626-636, 1994). Because some of these vectors do not require proliferating cells for gene transfer, dendritic cells are prepared by one of several methods available to those skilled in the art, such as preparation from peripheral blood over metrizamide gradient, culture of peripheral blood cells in GM-CSF and IL-4, and culture of CD34 cells in SCF, GM-CSF and TNF as described above.

Adeno Associated Viral Vectors

25 Adeno associated viruses (AAVs) require helper viruses such as adenovirus or herpes virus to achieve productive infection. In the absence of helper virus functions, AAV integrates (site-specifically) into a host cell's genome, but the integrated AAV genome has no pathogenic effect. The integration step allows the AAV genome to remain genetically intact until the host is exposed to the appropriate environmental conditions (e.g., a lytic helper virus), whereupon it re-enters the lytic life-cycle. Samulski (1993) *Current Opinion in Genetic and Development* 3:74-80 and the references cited therein provides an overview of the AAV life cycle. AAV-based vectors are used to transduce

cells with selected nucleic acids, *e.g.*, in the *in vitro* production of nucleic acids and peptides, and in *in vivo* and *ex vivo* gene therapy procedures. *See*, West *et al.* (1987) *Virology* 160:38-47; Carter *et al.* (1989) U.S. Patent No. 4,797,368; Carter *et al.* WO 93/24641 (1993); Kotin (1994) *Human Gene Therapy* 5:793-801; Muzyczka (1994) *J. Clin. Invest.* 94:1351 and Samulski (*supra*) for an overview of AAV vectors.

The viral vectors above can be recombinantly combined with expression cassettes comprising selected nucleic acids (*i.e.* proteins or peptides to be expressed in dendritic cells) and incubated with the stem cells to achieve transduction. Alternately, expression cassettes comprising selected nucleic acids are packaged into viral particles using packaging cell lines, which are optionally incubated with the stem cell.

Adenoviruses (Ads) have many attractive properties for the transfer of genes, including relatively simple production of high titres of the virus and vectors based upon the virus, and low pathogenicity. Ads are well-characterized viruses, and have been widely used as nucleic acid vectors (*reviewed in* Haddada *et al.* (1995) in *Current Topics in Microbiology and Immunology* Doerfler and Böhm (eds) Springer-Verlag, Heidelberg Germany; and Yu *et al.*, *Gene Therapy* (1994) 1:13-26. *See also*, Sharp and Wadell (1995) in *Principles and Practice of Clinical Virology*, Third Edition Zuckerman *et al.* (eds) John Wiley & Sons Ltd. and the references cited therein and Randrianarison-Jewtougoff and Pericaudet (1995) *Biologicals* 23: 145-157 and the references cited therein). One well-characterized Ad packaging cell line is the 293 cell line described in Haddada *et al.* (1995), *supra*. Ads are extrachromosomal viruses which do not integrate into the genome of cells transduced by the virus.

The culture of cells used in conjunction with the present invention, including cell lines and cultured cells from tissue or blood samples, including stem cells and dendritic cells is well known in the art. Freshney (*Culture of Animal Cells, a Manual of Basic Technique, third edition* Wiley-Liss, New York (1994)) and the references cited therein provides a general guide to the culture of cells. *See also*, Kuchler *et al.* (1977) *Biochemical Methods in Cell Culture and Virology*, Kuchler, R.J., Dowden, Hutchinson and Ross, Inc, and Inaba *et al.*, *supra*.

Differentiating Stem Cells into Dendritic Cells

Transduced stem cells are differentiated into dendritic cells by incubating the cells with the appropriate cytokines. Inaba *et al.* described the *in vitro* differentiation

of murine stem cells into dendritic cells by incubating the stem cells with murine GM-CSF. In brief, isolated stem cells are incubated with between 1 and 200 ng/ml murine GM-CSF, and preferably about 20 ng/ml GM-CSF in standard RPMI growth medium. The media is changed with fresh media about once every other day. After 7 days in culture, a large percentage of cells are dendritic, as assessed by expression of surface markers and morphology. Dendritic cells are isolated by florescence activated cell sorting (FACS) or by other standard methods.

Human cells CD34⁺ hematopoietic stem cells are preferably differentiated *in vitro* by culturing the cells with human GM-CSF and TNF- α . See, the examples and Szabolcs *et al.* (1995) 154: 5851-5861.

For mouse DCs, murine stem cells are differentiated into dendritic cells by incubating the stem cells in culture with murine GM-CSF. Typically, the concentration of GM-CSF in culture is at least about .2ng/ml, and preferably at least about 1 ng/ml. Often the range will be between about 20 ng/ml and 200 ng/ml. In many preferred embodiments, the dose will be about 100 ng/ml. IL-4 is optionally added in similar ranges for making murine DCs.

When human cells are transduced, human GM-CSF is used in similar ranges, and TNF- α is also added to facilitate differentiation. TNF- α is also typically added in about the same ranges. Optionally, SCF or other proliferation ligand (*e.g.*, Flt3) is added in similar dose ranges to make human DCs.

It will be appreciated that all of these dose ranges for differentiating stem cells are approximate. Different suppliers and different lots of cytokine from the same supplier vary in the activity of the cytokine. One of skill can easily titrate each cytokine which is used to determine the optimal dose for any particular cytokine. An example titration is performed in the Examples, *supra*.

Isolation of and expansion of T cells

T cells are isolated from mammals in some embodiments of the invention where the T cell is activated *in vitro* by contact with a dendritic cell of the invention. Several techniques are known. The expression of surface markers facilitates identification and purification of T cells. Methods of identification and isolation of T cells include FACS, incubation in flasks with fixed antibodies which bind the particular cell type and panning with magnetic beads.

In one method, Ficoll-Hypaque density gradient centrifugation is used to separate PBMC from red blood cells and neutrophils according to established procedures. Cells are washed with modified AIM-V (which consists of AIM-V (GIBCO) with 2 mM glutamine, 10 μ g/ml gentamicin sulfate, 50 μ g/ml streptomycin) supplemented with 1% fetal bovine serum (FBS). Enrichment for T cells is performed by negative or positive selection with appropriate monoclonal antibodies coupled to columns or magnetic beads according to standard techniques. An aliquot of cells is analyzed for cell surface phenotype including CD4, CD8, CD3 and CD14.

Cells are washed and resuspended at a concentration of 5×10^5 cells per ml of AIM-V modified as above and containing 5% FBS and 100 U/ml recombinant IL-2 (rIL-2) (supplemented AIM-V). Where the cells are isolated from an HIV+ patient, 25 nM CD4-PE40 (a recombinant protein consisting of the HIV-1-binding CD4 domain linked to the translocation and ADP-ribosylation domains of Pseudomonas aeruginosa exotoxin A), or other similar recombinant cytotoxic molecule which selectively hybridizes to HIV is added to the cell cultures for the remainder of the cell expansion to selectively remove HIV infected cells from the culture. CD4-PE40 has been shown to inhibit p24 production in HIV-1-infected cell cultures and to selectively kill HIV-1-infected cells.

To stimulate proliferation, OKT3 monoclonal antibody (Ortho Diagnostics) is added to a concentration of 10 ng/ml and the cells are plated in 24 well plates with 0.5 ml per well. The cells are cultured at 37°C in a humidified incubator with 5% CO₂ for 48 hours. Media is aspirated from the cells and 1 ml of vector-containing supernatant (described below) supplemented with 5 μ l/ml of protamine sulfate, 100 U/ml rIL-2, 100 U/ml penicillin, 0.25 μ g/ml amphotericin B/ml and an additional 100 μ g/ml streptomycin (25 nM CD4-PE40 can be added as described above).

Isolating Cells With Selectable Markers

A variety of cells are used in the methods of the invention, including stem cells, T cells and dendritic cells. Each of these cell types is characterized by expression of particular markers on the surface of the cell, and lack of expression of other markers. For instance, human stem cells typically express CD34 antigen. dendritic cells express MHC molecules and costimulatory molecules (*e.g.*, B7-1 and B7-2), a lack of markers specific for granulocytes, NK cells, B cells, and T cells. In the mouse, some (but not all) dendritic cells express 33D1 (DC from spleen and Peyer's patch, but not skin or thymic

medulla), NLDC145 (DC in skin and T-dependent regions of several lymphoid organs and CD11c (CD11c also reacts with macrophage). T cells are positive for various markers depending on the particular subtype, most notably CD4 and CD8.

The expression of surface markers facilitates identification and purification of these cells. These methods of identification and isolation include FACS, column chromatography, panning with magnetic beads, western blots, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and the like, and various immunological methods such as fluid or gel precipitin reactions, immunodiffusion (single or double), immunoelectrophoresis, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, and the like. For a review of immunological and immunoassay procedures in general, see Stites and Terr (eds.) 1991 *Basic and Clinical Immunology* (7th ed.) and Paul *supra*. For a discussion of how to make antibodies to selected antigens *see, e.g.* Coligan (1991) *Current Protocols in Immunology* Wiley/Greene, NY; and Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press, NY; Stites et al. (eds.) *Basic and Clinical Immunology* (4th ed.)

Cell isolation or immunoassays for detection of cells during cell purification can be performed in any of several configurations, *e.g.*, those reviewed in Maggio (ed.) (1980) *Enzyme Immunoassay* CRC Press, Boca Raton, Florida; Tijan (1985) "Practice and Theory of Enzyme Immunoassays," *Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers B.V., Amsterdam; Harlow and Lane, *supra*; Chan (ed.) (1987) *Immunoassay: A Practical Guide* Academic Press, Orlando, FL; Price and Newman (eds.) (1991) *Principles and Practice of Immunoassays* Stockton Press, NY; and Ngo (ed.) (1988) *Non-isotopic Immunoassays* Plenum Press, NY.

Most preferably, cells are isolated and characterized by flow cytometry methods such as a FACS analysis. A wide variety of flow-cytometry methods are known. For a general overview of fluorescence activated flow cytometry *see, for example*, Abbas *et al.* (1991) *Cellular and Molecular immunology* W.B. Saunders Company, particularly chapter 3, and Kuby (1992) *Immunology* W.H. Freeman and Company, particularly chapter 6. FACS machines are available, *e.g.*, from Becton Dickinson.

Labeling agents which can be used to label cell antigen include *e.g.*, monoclonal antibodies, a polyclonal antibodies, proteins, or other polymers such as affinity matrices, carbohydrates or lipids. Detection proceeds by any known method, such as immunoblotting, western blot analysis, tracking of radioactive or bioluminescent markers, capillary electrophoresis, or other methods which track a molecule based upon size, charge or affinity. The particular label or detectable group used and the particular assay are not critical aspects of the invention. The detectable moiety can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of gels, columns, solid substrates cell cytometry and immunoassays and, in general, any label useful in such methods can be applied to the present invention. Thus, a label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include magnetic beads (*e.g.* DynabeadsTM), fluorescent dyes (*e.g.*, fluorescein isothiocyanate, Texas red, rhodamine, and the like), radiolabels (*e.g.*, ³H, ¹²⁵I, ³⁵S, ¹⁴C, or ³²P), enzymes (*e.g.*, LacZ, CAT, horse radish peroxidase, alkaline phosphatase and others, commonly used as detectable enzymes, either as marker gene products or in an ELISA), nucleic acid intercalators (*e.g.*, ethidium bromide) and colorimetric labels such as colloidal gold or colored glass or plastic (*e.g.* polystyrene, polypropylene, latex, *etc.*) beads.

The label is coupled directly or indirectly to the desired component of the assay according to methods well known in the art. As indicated above, a wide variety of labels are used, with the choice of label depending on the sensitivity required, ease of conjugation of the compound, stability requirements, available instrumentation, and disposal provisions. Non radioactive labels are often attached by indirect means. Generally, a ligand molecule (*e.g.*, biotin) is covalently bound to a polymer. The ligand then binds to an anti-ligand (*e.g.*, streptavidin) molecule which is either inherently detectable or covalently bound to a signal system, such as a detectable enzyme, a fluorescent compound, or a chemiluminescent compound. A number of ligands and anti-ligands can be used. Where a ligand has a natural anti-ligand, for example, biotin, thyroxine, and cortisol, it can be used in conjunction with labeled, anti-ligands. Alternatively, any haptenic or antigenic compound can be used in combination with an antibody.

Labels can also be conjugated directly to signal generating compounds, e.g., by conjugation with an enzyme or fluorophore. Enzymes of interest as labels will primarily be hydrolases, particularly phosphatases, esterases and glycosidases, or oxidoreductases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc. Chemiluminescent compounds include luciferin, and 2,3-dihydrophthalazinediones, e.g., luminol. For a review of various labelling or signal producing systems which are used, see, U.S. Patent No. 4,391,904, which is incorporated herein by reference.

Means of detecting labels are well known to those of skill in the art. Thus, for example, where the label is a radioactive label, means for detection include a scintillation counter or photographic film as in autoradiography. Where the label is a fluorescent label, it is optionally detected by exciting the fluorochrome with the appropriate wavelength of light and detecting the resulting fluorescence, e.g., by microscopy, visual inspection, via photographic film, by the use of electronic detectors such as charge coupled devices (CCDs) or photomultipliers and the like. Similarly, enzymatic labels are detected by providing appropriate substrates for the enzyme and detecting the resulting reaction product.

Finally, simple colorimetric labels are often detected simply by observing the color associated with the label. Thus, in various dipstick assays, conjugated gold often appears pink, while various conjugated beads appear the color of the bead.

Some assay formats do not require the use of labeled components. For instance, agglutination assays can be used to detect the presence of antibodies. In this case, cells are agglutinated by samples comprising the antibodies bound to the cells. In this format, none of the components need be labeled and the presence of the target antibody is detected by simple visual inspection.

Depending upon the assay, various components, including the antibody, or anti-antibody, are typically bound to a solid surface. For instance, in one preferred embodiment, unwanted cells are panned out of bone marrow using appropriate antibodies bound to a substrate over which the cells are passed. Many methods for immobilizing biomolecules to a variety of solid surfaces are known in the art. For instance, the solid surface is optionally a membrane (e.g., nitrocellulose), a microtiter dish (e.g., PVC, polypropylene, or polystyrene), a test tube (glass or plastic), a dipstick (e.g. glass, PVC,

polypropylene, polystyrene, latex, and the like), a microcentrifuge tube, a flask, or a glass, silica, plastic, metallic or polymer bead. The desired component is optionally covalently bound, or noncovalently attached through nonspecific bonding. A wide variety of organic and inorganic polymers, both natural and synthetic are optionally employed as the material for the solid surface. Illustrative polymers include polyethylene, polypropylene, poly(4-methylbutene), polystyrene, polymethacrylate, poly(ethylene terephthalate), rayon, nylon, poly(vinyl butyrate), polyvinylidene difluoride (PVDF), silicones, polyformaldehyde, cellulose, cellulose acetate, nitrocellulose, and the like. Other materials which are appropriate depending on the assay include paper, glasses, ceramics, metals, metalloids, semiconductive materials, cements and the like. In addition, substances that form gels, such as proteins (*e.g.*, gelatins), lipopolysaccharides, silicates, agarose and polyacrylamides can be used. Polymers which form several aqueous phases, such as dextrans, polyalkylene glycols or surfactants, such as phospholipids, long chain (12-24 carbon atoms) alkyl ammonium salts and the like are also suitable.

Diagnostic Assays

In one embodiment, diagnostic assays are provided. These assays are used to determine whether a cell population (*e.g.*, a blood or cell sample from a patient) express a selected antigen. In the assays, recombinant dendritic cells expressing the selected antigen are used to activate T-cells against the antigen. The cell population is then exposed to the activated T-cells, and lysis of the cells is monitored (*e.g.*, by trypan blue exclusion). If the observed lysis is higher than an appropriate control, the population of cells comprises the antigen. This can be used, *e.g.*, to assess whether tumor cells express a particular antigen. If the tumor is found to express a particular antigen, a clinician can use the information to better select therapeutics against the tumor.

These diagnostic assays can be used in conjunction with the therapeutic aspects of the invention, *i.e.*, a tumor sample can be screened against a panel of activated T-cells to determine which activated T-cells or recombinant DCs can be used to immunize against the tumor.

Immunizations can also be monitored with recombinant DCs. Precursor frequency and/or T-cell reactivity is monitored by exposure to recombinant DCs, *e.g.*,

using DCs corresponding to the DCs which were used for immunization or to stimulate T-cells.

Making Expression Cassettes

Many recombinant expression cassettes are known to persons of skill.

- 5 These can be made using standard recombinant or synthetic techniques, and one of skill can construct a variety of clones containing functionally equivalent nucleic acids, such as nucleic acids which encode the same polypeptide. Cloning methodologies to accomplish these ends, and sequencing methods to verify the sequence of nucleic acids are well known in the art. Examples of appropriate cloning and sequencing techniques, and
- 10 instructions sufficient to direct persons of skill through many cloning exercises are found in Berger, Sambrook and Ausbel (*all supra*). The nucleic acid compositions of this invention, whether RNA, DNA, cDNA, genomic DNA, or a hybrid of the various combinations, are isolated from biological sources or synthesized *in vitro*. The nucleic acids of the invention are present in transformed or transfected cells, in transformed or
- 15 transfected cell lysates, or in a partially purified or substantially pure form.

- In vitro* amplification techniques suitable for amplifying sequences to be subcloned into an expression vector are known. Examples of techniques sufficient to direct persons of skill through such *in vitro* amplification methods, including the polymerase chain reaction (PCR) the ligase chain reaction (LCR), Q β -replicase
- 20 amplification and other RNA polymerase mediated techniques (*e.g.*, NASBA) are found in Berger, Sambrook *et al.* (1989) *Molecular Cloning - A Laboratory Manual* (2nd Ed) Vol. 1-3; and Ausubel, as well as Mullis *et al.*, (1987) U.S. Patent No. 4,683,202; *PCR Protocols A Guide to Methods and Applications* (Innis *et al.* eds) Academic Press Inc. San Diego, CA (1990) (Innis); Arnheim & Levinson (October 1, 1990) *C&EN* 36-47; *The*
- 25 *Journal Of NIH Research* (1991) 3, 81-94; (Kwoh *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86, 1173; Guatelli *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87, 1874; Lomell *et al.* (1989) *J. Clin. Chem* 35, 1826; Landegren *et al.*, (1988) *Science* 241, 1077-1080; Van Brunt (1990) *Biotechnology* 8, 291-294; Wu and Wallace, (1989) *Gene* 4, 560; Barringer *et al.* (1990) *Gene* 89, 117, and Sooknanan and Malek (1995) *Biotechnology* 13: 563-564.
- 30 Improved methods of cloning *in vitro* amplified nucleic acids are described in Wallace *et al.*, U.S. Pat. No. 5,426,039.

Nucleic acid synthesis techniques are available, such as the solid phase phosphoramidite triester method described by Beaucage and Caruthers (1981), *Tetrahedron Letts.*, 22(20):1859-1862, *e.g.*, using an automated synthesizer, *e.g.*, as described in Needham-VanDevanter *et al.* (1984) *Nucleic Acids Res.*, 12:6159-6168.

- 5 Nucleic acids can also be custom made and ordered from a variety of commercial sources known to persons of skill. Purification of oligonucleotides, where necessary, is typically performed by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson and Regnier (1983) *J. Chrom.* 255:137-149. The sequence of the synthetic oligonucleotides can be verified using the chemical degradation method of
- 10 Maxam and Gilbert (1980) in Grossman and Moldave (eds.) Academic Press, New York, *Methods in Enzymology* 65:499-560.

- One of skill will recognize many ways of generating alterations in a given nucleic acid sequence such as a known cancer marker. Such well-known methods include site-directed mutagenesis, PCR amplification using degenerate oligonucleotides, exposure
- 15 of cells containing the nucleic acid to mutagenic agents or radiation, chemical synthesis of a desired oligonucleotide (*e.g.*, in conjunction with ligation and/or cloning to generate large nucleic acids) and other well-known techniques. *See*, Gilman and Smith (1979) *Gene* 8:81-97; Roberts *et al.* (1987) *Nature* 328:731-734 and Sambrook *et al.* (1989) *Molecular Cloning - A Laboratory Manual* (2nd Ed) Vol. 1-3; Innis, Ausbel, Berger,
- 20 Needham VanDevanter and Mullis (*all supra*).

- In addition to recombinant expression, polypeptides of the invention can be synthetically prepared in a wide variety of well-known ways. Polypeptides of relatively short size are typically synthesized in solution or on a solid support in accordance with conventional techniques. *See, e.g.*, Merrifield (1963) *J. Am. Chem. Soc.* 85:2149-2154.
- 25 Various automatic synthesizers and sequencers are commercially available and can be used in accordance with known protocols. *See, e.g.*, Stewart and Young (1984) *Solid Phase Peptide Synthesis*, 2d. ed., Pierce Chemical Co. Polypeptides are also produced by recombinant expression of a nucleic acid encoding the polypeptide followed by purification using standard techniques.

- 30 The Expression cassette used to transform the host cell preferably contains DNA sequences to initiate transcription and sequences to control the translation of any encoded antigenic protein or peptide sequence. These sequences are referred to as

expression control sequences. When illustrative expression control sequences active in mammalian cells are obtained from the SV-40 promoter (*Science*, 222:524-527, 1983), the CMV I.E. Promoter (*Proc. Natl. Acad. Sci.* 81:659-663, 1984) and the metallothionein promoter (*Nature* 296:39-42, 1982). Pol III promoters such as tRNA_{val}, a house-keeping cellular gene promoter, and the adenovirus VA1, a strong viral promoter are also desirable. The cloning vector containing the expression control sequences is cleaved using restriction enzymes and adjusted in size as necessary or desirable and ligated with nucleic acid coding for the target polypeptides by means well known in the art.

Polyadenylation or transcription terminator sequences from known mammalian genes are typically incorporated into the vector. Pol III termination sequences are outlined in Geiduschek, E.P., *Ann. Rev. Biochem.* 57:873-914 (1988). An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript are also be included. An example of a splicing sequence is the VPI intron from SV40 (Sprague, J. *et al.*, 1983, *J. Virol.* 45: 773-781).

Additionally, sequences to control replication in the host cell is optionally incorporated into the vector such as those found in bovine papilloma virus type-vectors. Saveria-Campo, M., 1985, "Bovine Papilloma virus DNA a Eukaryotic Cloning Vector" in *DNA Cloning Vol. II a Practical Approach* Ed. D.M. Glover, IRL Press, Arlington, Virginia pp. 213-238.

Where a retroviral packaging vector is used, a packaging site containing the nucleic acids responsible for packaging viral RNA into the retroviral particle is included with the expression cassette. Typically, this includes nucleic acids corresponding to those from a retrovirus located between the LTR of the retrovirus and the *gag* initiation codon.

MLR Assays

In order to determine the antigen presenting cell activity of antigen presenting cells such as DC, the proliferative effect of these antigen presenting cells on T cells is tested in an MLR assay. MLR assays or "mixed lymphocyte response" assays are the standard *in vitro* assay of antigen presenting function in cellular immunity. The assay measures the proliferation of T cells after stimulation by a selected cell type. The number of T cells produced are typically characterized by measuring T cell proliferation

based on incorporation of ^3H -thymidine in culture. Similar methods are used *in vivo* in nude or SCID mouse models. *See also*, Paul (*supra*) at chapter 31.

Ex Vivo Therapy

Ex vivo therapeutic methods for making transformed dendritic cells and
5 activated T cells are provided. In the methods, dendritic cells are transformed *in vitro*. These transformed dendritic cells are used to activate T cells *in vitro*, or the dendritic cells are introduced into a mammal to activate the T cell *in vivo*. T cells such as CD8⁺ CTLs activated *in vitro* are introduced into a mammal where they are cytotoxic against target cells bearing antigenic peptides corresponding to those the T cells are activated to
10 recognize on class I MHC molecules. These target cells are typically cancer cells, or infected cells which express unique antigenic peptides on their MHC class I surfaces. It is shown herein that dendritic cells expressing cancer antigens activate T-cells against corresponding cancers.

Similarly, helper T-cells (*e.g.*, CD4⁺ T cells), which recognize antigenic
15 peptides in the context of MHC class II, are also stimulated by the recombinant DCs, which comprise antigenic peptides both in the context of class I and class II MHC. These helper T-cells also stimulate an immune response against a target cell. As with cytotoxic T-cells, helper T-cells are stimulated with the recombinant DCs *in vitro* or *in vivo*.

The dendritic cells and T cells are preferably isolated from the mammal
20 into which the activated T cells are to be active ("autologous" therapy). Alternatively, the cells can be those from a donor or stored in a cell bank (*e.g.*, a blood bank).

Thus, a patient infected with a virus such as HIV-1 or suffering from a cancer such as a melanoma can be treated by administering recombinant dendritic cells, or by using recombinant dendritic cells to activate a population of the patient's T cells
25 against the infection or cancer, and introducing the T cells back into the patient as described herein. Thus, the present invention provides a method of producing cytotoxic T cells *in vitro*, *ex vivo* or *in vivo*.

In Vivo Therapy

T cells or dendritic cells can be administered directly to the organism to
30 produce T cells active against a selected cancerous or infected cell type. Administration of these is by any of the routes normally used for introducing a cell into ultimate contact with a mammal's blood or tissue cells.

The cells are administered in any suitable manner, often with pharmaceutically acceptable carriers. Suitable methods of administering cells in the context of the present invention to a patient are available, and, although more than one route can be used to administer a particular cell composition, a particular route can often
5 provide a more immediate and more effective reaction than another route.

Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention. Most typically, quality controls
10 (microbiology, clonogenic assays, viability tests), are performed and the cells are reinfused back to the patient, preceded by the administration of diphenhydramine and hydrocortisone. See, for example, Korbling, M. *et al.* (1986) *Blood*, 67:529-532 and Haas *et al.* (1990) *Exp. Hematol.* 18:94-98.

Formulations suitable for parenteral administration, such as, for example,
15 by intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, and carriers include aqueous isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-
aqueous sterile suspensions that can include suspending agents, solubilizers, thickening
20 agents, stabilizers, and preservatives. Intravenous or intraperitoneal administration are the preferred method of administration for dendritic or T cells of the invention.

The dose of cells (*e.g.*, activated T cells, or dendritic cells) administered to a patient, in the context of the present invention should be sufficient to effect a beneficial therapeutic response in the patient over time, or to inhibit growth of cancer cells, or to
25 inhibit infection. Thus, cells are administered to a patient in an amount sufficient to elicit an effective CTL response to the virus or tumor antigen and/or to alleviate, reduce, cure or at least partially arrest symptoms and/or complications from the disease or infection. An amount adequate to accomplish this is defined as a "therapeutically effective dose." The dose will be determined by the activity of the T cell or dendritic cell produced and
30 the condition of the patient, as well as the body weight or surface area of the patient to be treated. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular cell in a

particular patient. In determining the effective amount of the cell to be administered in the treatment or prophylaxis of diseases such as AIDS or cancer (*e.g.*, metastatic melanoma, prostate cancer, *etc.*), the physician needs to evaluate circulating plasma levels, CTL toxicity, progression of the disease, and the production of immune response
5 against any introduced cell type.

Prior to infusion, blood samples are obtained and saved for analysis. Generally at least about 10^4 to 10^6 and typically, between 1×10^8 and 1×10^{10} cells are infused intravenously or intraperitoneally into a 70 kg patient over roughly 60-120 minutes. Intravenous infusion is preferred. Vital signs and oxygen saturation by pulse
10 oximetry are closely monitored. Blood samples are obtained 5 minutes and 1 hour following infusion and saved for analysis. Cell reinfusion are repeated roughly every month for a total of 10-12 treatments in a one year period. After the first treatment, infusions can be performed on an outpatient basis at the discretion of the clinician. If the reinfusion is given as an outpatient, the participant is monitored for at least 4 hours
15 following the therapy.

For administration, cells of the present invention can be administered at a rate determined by the LD-50 (or other measure of toxicity) of the cell type, and the side-effects of the cell type at various concentrations, as applied to the mass and overall health of the patient. Administration can be accomplished via single or divided doses. The cells
20 of this invention can supplement other treatments for a condition by known conventional therapy, including cytotoxic agents, nucleotide analogues and biologic response modifiers. Similarly, biological response modifiers are optionally added for treatment by the DCs or activated T cells of the invention. For example, the cells are optionally administered with an adjuvant, or cytokine such as GM-CSF, IL-12 or IL-2.

25 The studies presented herein demonstrate that tumor antigen genes are expressed by dendritic cells using retroviral transduction, and that these dendritic cells (and T cells activated by the dendritic cells) can be used as anti-tumor therapeutics. Transduced dendritic cells are valuable reagents for active immunization strategies against cancer and infectious diseases, and are useful *in vitro* to uncover unique tumor epitopes
30 and antigens, and as a tool to study the basic biology of primary dendritic cells. Accordingly, in one specific example of the administration methods shown above, metastatic melanoma patients are immunized with autologous dendritic cells transduced

with the MART-1 or GP100 tumor antigen genes to inhibit melanoma metastasis and disease progression, or, alternatively, melanoma patients are immunized with activated T cells (or both activated T-cells and dendritic cells) transduced with the MART-1 or GP100 tumor antigen genes to inhibit melanoma metastasis and disease progression, using the dosing and administration methods set forth above.

In Vitro Assays And Kits

The present invention provides commercially valuable assays and kits to practice the assays. In the assays of the invention, dendritic cells are transformed with a nucleic acid encoding a putative T cell MHC class I associated antigen. The dendritic cell is used to activate the T cell, which is then tested for cytotoxic activity against a class of target cells thought to comprise the putative antigen. Cytotoxicity indicates that the target cells comprise the antigen, and that the antigen is sufficient to mediate a T cell recognition of the target cell. This assay provides investigators with a lead molecule for use in gene therapy or vaccination therapies. Because the transformed dendritic cells can be established in culture, or made in batches, several potential target cell populations can be screened. Thus, libraries of potential tumor antigens can be screened by cloning into dendritic cells. The ability to screen and identify tumor antigens is of considerable commercial value to pharmaceutical and other drug discovery companies.

Kits based on the assay are also provided. The kits typically include a container, and stem cells or dendritic cells. The kits optionally comprise directions for performing the assays, stem cell transformation vectors, cytokines, or instructions in the use of any of these components, or the like.

EXAMPLES

The following examples are provided by way of illustration only and not by way of limitation. Those of skill will readily recognize a variety of noncritical parameters which can be changed or modified to yield essentially similar results.

Example 1: Differentiation of Bone Marrow Cells into Dendritic Cells *in Vitro*

Freshly isolated dendritic cells from peripheral blood are difficult to transduce, particularly with common retroviral vectors, because they are non-dividing. Accordingly, a novel approach to transforming dendritic cells was derived. Stem cells were transduced, and then differentiated into dendritic cells. The following procedure

was used to differentiate bone marrow cells isolated from mice into dendritic cells *in vitro*.

Bone marrow was harvested from 5 BALB-C mice. To remove B cells, T cells, granulocytes, and Ia⁺ cells, the bone marrow cells were incubated with an antibody cocktail against CD8, CD4, CD45R (pan B cell), GR-1 (granulocyte), and Ia^d (all antibodies were of rat origin except anti-Ia from mouse). All antibodies were obtained from Cedar Lane (Canada). The bone marrow cells were then incubated on a mouse anti-rat flask to remove rat antibody-bound cells, followed by an incubation of the non-adherent cells in a goat anti-mouse flask to remove cells labeled with anti-mouse antibodies. As an alternative method to remove unwanted cells, rabbit complement was added at a 1:10 ratio at 37°C following incubation with the antibodies. Non-adherent cells were then cultured in RPMI with 5% fetal calf serum containing 3.3 to 20 ng/ml mGM-CSF. Every two days, the medium was changed with fresh medium containing fresh GM-CSF, and non-adherent cells (typically granulocytes) were removed. At day 6, moderately adherent cells (dendritic cells) were removed by gentle pipetting, and replated. Adherent cells (macrophage) were left on the plate. On day 7, the dendritic cells were phenotyped by FACS analysis and microscopy, which confirmed a dendritic phenotype, and that B7-1⁺, B7-2⁺ and Cd11c⁺ dendritic cells were present. Typically, 5x10⁶ dendritic cells were obtained by day 7.

In one variation, GM-CSF was titrated over a range of 200, 20, 2, and .2 ng/ml, and the contaminating granulocytes (which are completely non adherent, as opposed to lightly adherent dendritic clumps) were removed during differentiation by performing extra washes. In addition, a procedure which substituted rat anti-Ia^d antibody was used, so that only a single mouse anti-rat flask was needed.

The percent of cells in the final cultures that were dendritic cells by morphology was also affected by the level of GM-CSF, with 62% appearing dendritic at 200 ng/ml, 60% appearing dendritic at 20 ng/ml; 44% appearing dendritic at 2 ng/ml, and 6% appearing dendritic at .2 ng/ml. Thus, typically, at least 2 ng GM-CSF is used in culture, and preferably, at least about 20 ng/ml. The percent which showed dendritic markers by FACS were similar:

Table 1: Phenotypic Analysis by FACS

| Antibody | DC ¹ : 200 ng/ml GM- CSF | DC: 20ng/ml GM-CSF | DC: 2 ng/ml GM-CSF | DC: .2 ng /ml GM- CSF | Spleno- cytes |
|--------------------------|---|-----------------------|-----------------------|-----------------------------|------------------|
| Total B7-2 | 67% | 65% | 44% | 7% | 51% |
| Total Ia ^d | 60% | 55% | 41% | 7% | 38% |
| 5 Thy 1.2 | 51% | 49% | 35% | 5% | 10% |
| B7-2 and Ia ^d | 25% | 20% | 10% | 4% | 48% |
| Gr-1 (granulocyte) | 16% | 21% | 24% | 89% | 17% |
| B220 (B-cell) | 18% | 15% | 13% | 11% | 38% |
| Total MAC-1 | 76% | 84% | 83% | 82% | 8% |
| 10 Total B7-1 | 54% | 48% | 29% | 8% | 1% |
| B7-1 pos/MAC neg | 8% | 5% | 3% | 0% | 1% |

¹DC = dendritic cells.^dhigh background with IgG control on splenocytes

15 In this experiment, an MLR assay was performed as described above for each GM-CSF titration. The results are shown in Figure 1. As seen from the results, .2 ng/ml GM-CSF promotes inefficient differentiation into functional dendritic cells. Thus, about 2ng/ml or more is preferred.

20 To show that the dendritic cells were functional, the activity of the cells was tested in a standard mixed leukocyte reaction (MLR) assay as in Inaba *et al.* (1992) *supra*. Stimulator cells in the MLR were day 7 BALB dendritic cells vs BALB splenocytes (1500 rads). Responders were C57B1/6 splenocytes purified for T cells on an R&D systems negative selection column (MTCC-1000) using the manufacturer's directions. The column contained antibodies to remove B cells, granulocytes and

25 macrophage. Thus, T cells pass through the column. The stimulators and responders were plated in standard 96 well plates at ratios of 1:5, 1:20, 1:80 and 1:320 using 3X10⁵ responders/well. Four days after plating, the cells were pulsed with ³H-thymidine at 1 μ Ci/well. Proliferation was then measured by monitoring thymidine uptake. The results are shown in Figure 2 (T cell alone and dendritic cell alone values were subtracted). As

the results show, the dendritic cells dramatically stimulated proliferation, while the splenocytes have no proliferative effect. Thus, the dendritic cells were functional, *i.e.*, they induced proliferation in T-cells.

Thus, dendritic cells were cultured from murine bone marrow using GM-CSF (see also, Inaba, 1992, *supra*). Bone marrow-derived cells express B7-1, B7-2, Ia and Cd11c, and have characteristic dendritic morphology. Bone marrow derived dendritic cells act as antigen presenting cells, with high levels of T cell activation as measured in a standard MLR assay.

Example 2: Transduction of Bone-Marrow Derived Dendritic Cells

Primary, mature dendritic cells are difficult to gene modify using existing techniques. Accordingly, the present invention provides a new strategy for genetic modification of dendritic cells. In the methods of the invention, hematopoietic stem cells are gene modified, and differentiated into dendritic cells. It is demonstrated herein that this novel technique generated dendritic cells expressing foreign genes. MART-1 and GP100 melanoma antigens were expressed by dendritic cells, and these cells stimulated MART-1- and GP100-specific T-cells, and generated specific T-cells from resting lymphocytes. In murine tumor models, dendritic cells, gene modified with a model tumor antigen, effectively immunized against established tumors. This technique allowed the generation of specific T-cells against common tumors and provides a novel method to actively immunize patients against known tumor antigens, *i.e.*, by utilizing dendritic cells transduced with antigen or cytokine genes, or *ex vivo* activated T-cells.

Murine Dendritic Cell Studies: Murine bone marrow cells were successfully transduced with a retroviral vector encoding the β -galactosidase model tumor antigen. Following *in vitro* differentiation into dendritic cells using GM-CSF, supplemented by IL-4, 30-40% of dendritic cells were positive for β -galactosidase expression. In addition, T-cells specific for β -galactosidase expressed large amounts of cytokines such as IFN- γ when co-cultured with the transduced but not the non-transduced dendritic cells. These studies indicated that dendritic cells were transduced using these methods to express foreign genes.

In one series of experiments, 50 BALB/c mice were injected intraperitoneally with 5-fluorouracil (5FU, Sigma Chemical CO. St. Louis, MO) at 3 mg/mouse (150 mg/kg) (the 5FU injection is optional). After two days, bone marrow

was harvested. 7×10^6 cells per mouse were obtained. Cells were co-cultured on irradiated ecotropic LZSN packaging cells (LZSN contains the β -gal gene) for two days. The vector was introduced into the GP+E86 ecotropic packaging cell line. See, Miller (1989) *Biotechniques* 7: 980; Miller (1986) *Mol. Cell Biol.* 6:2895; Markowitz (1988) *J. Virol.* 62: 420, and Wang *et al.* (1995) *J. Immunol.* Each day, fresh ecotropic supernatant was added, followed by centrifugation for 1 hour at 1000 g. The supernatant was supplemented with polybrene and 20 ng/ml GM-CSF. On day 2, cells were harvested, and dead cells were removed with Ficoll. The live cells were replated at 20 ng/ml GM-CSF.

Table 2: Cytokine Release from β -gal specific T-cell Clone in Response to Murine Dendritic Cells Transduced with the β -gal Gene

| Stimulator | Responder [mIFN- γ production; U/ml 1×10^5 T-cells/18 Hours] | |
|-----------------------------|---|--------------------------------|
| | None | Beta-gal specific T-cell clone |
| None | 0 | 5 |
| DC NV | 0 | 67 |
| DC; β -gal transduced | 0 | 64,600 |

In another series of experiments, bone marrow was harvested from femur and tibia as described, *supra*. Lymphocytes and Ia+ cells were removed. Bone marrow cells were co-cultured on irradiated ecotropic bgal producer cells for 2 days, in the presence of murine GM-CSF, murine IL-4 and lipofectamine. Cells were harvested and replated with fresh mGM-CSF and mIL-4. On day 6, cells were harvested, pelleted, and replated in fresh media. Cells were assayed and used for therapy on day 7.

On day 7, the resulting dendritic cells were stained with X-gal. Cells that were morphologically dendritic were positive for X gal as examined by light microscopy. 38% of the cells were positive. Thus, the dendritic cells were transformed with the foreign X-gal gene which had been used to transform the hematopoietic stem cells. As shown in Table 3, co-culturing provided better transformation than supernatant transduction alone.

Table 3: Percent of Murine Dendritic Cells Transduced with β -gal Retrovirus

| Experiment | Nontransduced | β -gal transduced | |
|------------|---------------|-------------------------|-------------|
| | | Supernatant | Co-cultured |
| #1 | 0 | 8 | 28 |
| #2 | 0 | N.D. | 38 |

N.D. = Not Done

To demonstrate that transduced dendritic cells presented antigen, 1×10^5 dendritic cells were co-cultured with 1×10^5 H-2^d T cells specific for beta gal. After 24 hours of co-culture, the supernatants were assayed for murine IFN- γ . A large amount of IFN- γ was present in the supernatant (34,650 pg/ml) upon co-culture with T cells, as compared to controls (controls had 3,561 and 6,761 pg/ml; *see*, Table 4).

Table 4: Cytokine Release from β -gal specific T cell Clone in Response to Murine Dendritic Cells Transduced with the β -gal gene

| Stimulator | Responder | |
|-------------------------------|--|------------------------------------|
| | (mIFN- γ production; pg/ml/ 1×10^8 T cells/17 hours) | |
| Stimulator | None | β -gal specific T cell Clone |
| none | 0 | 3561 |
| DC NV | 1 | 6671 |
| DC; β -gal transduced | 1 | 34,650 |
| CT26; β -gal transduced | 0 | 75,550 |

To study the ability of transduced dendritic cells to immunize *in vivo*, mice were immunized on day 0 with PBS, untransduced dendritic cells (3×10^5 per mouse), beta gal-transduced dendritic cells (3×10^5 per mouse), or irradiated lac Z (LZSN) producer cells (3×10^5 per mouse, to show that any producer cells which were transferred from the dendritic cell co-culture were not responsible for immunization). On day 21, mice were challenged by IV with 10^5 beta gal CT26 mouse tumor line cells (Wang *et al.* (1995) *Journal of Immunology*). These CT26 cells were beta gal positive; thus, T cells activated against CT26 tumor cells will destroy the cells.

On day 33, mice were sacrificed and lung metastases were counted. Mice immunized with beta-gal transduced dendritic cells had statistically lower numbers of metastases compared to the PBS and LZSN producer cell lines (Table 5).

Table 5: Immunization Followed by Challenge 21 Days Later

| 5 | Immunized with | Challenged with | n | mean # lung |
|----|-------------------------------|------------------------------|---|-------------|
| | (day 0) | (day 21) | | metastases |
| | PBS | β -gal transduced CT26 | 6 | 175 |
| | Dendritic Cells NV | | 5 | 61• |
| | β -gal transduced DC | | 6 | 1 |
| 10 | Irradiated LZSN Producer Line | | 7 | 158 |

Example 3: Treatment of Established Pulmonary Metastases with Transduced Dendritic Cells

Dendritic cells were retrovirally transduced with the model tumor antigen β -galactosidase, or with a control retrovirus expressing the rat Neu gene. BALB/c mice were injected i.v. with 3×10^5 β gal-transduced CT26 tumor cells (C-25). Three and 6 days following tumor injection, mice were immunized with β gal- or neu-transduced dendritic cells. Twelve days following tumor injection, mice were sacrificed and pulmonary metastases were counted. Mice treated with β gal-transduced DC exhibited a significant reduction in pulmonary metastases compared to the control group (Figure 6). In addition, β gal-specific T-cells were isolated from the spleens of mice immunized with β gal-transduced DC.

3-day lung met model summary:

D-0: BALB/c mice given 3×10^5 C25 (CT26/bgal) IV

25 D-3: Mice treated with 4×10^5 DC/mouse IV

D-6: Mice again treated with 4×10^5 DC/mouse IV

D-12: Lung mets counted

Methods

Cell Lines. CT26.CL25 (C-25) is a subclone of the CT26.WT, a BALB/c (H-2d)

30 undifferentiated colon carcinoma stably transduced with a retrovirus encoding the lacZ

gene. Cell lines were maintained in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 2 mmol/L glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin (all from Biofluids, Rockville MD), 1.25 mg/ml amphotericin B (Fungizone; Life Technologies, Inc., Grand Island, NY), and 50 mg/ml gentamicin sulfate (Life Technologies, Inc.) (CM). CT26.CL25 were maintained in the presence of 400 mg/ml G418 (Geneticin; Life Technologies, Inc.).

Bone Marrow-Derived Dendritic Cell Isolation. DC were prepared from bone marrow as described by Inaba *et al.*, with some modifications. Briefly, bone marrow was flushed out from the long bones of the hind limbs and depleted of red cells with ACK lysing buffer (Biofluids). Bone marrow cells were depleted of lymphocytes and Ia⁺ cells using a mixture of rabbit anti-mouse lymphocyte serum and anti-mouse Iak alloantiserum, and rabbit complement (both from Accurate Chemical and Scientific Corp., Westbury, NY). Cells were cultured in RPMI 1640 supplemented with 5% heat-inactivated fetal bovine serum, 2 mmol/L glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 1.25 mg/ml amphotericin B, 50 mg/ml gentamicin sulfate, and 5 x10⁻⁵ mM 2-mercaptoethanol (2-ME; Life Technologies, Inc.) supplemented with 20 ng/ml recombinant murine granulocyte-macrophage colony stimulating factor (rmGM-CSF) and 100 ng/ml recombinant murine interleukin 4 (rmIL-4) (both from Peprotech, Rocky Hill, NJ). Cells were plated at 7 x 10⁵ cells/ml with 5 ml/well in 6 well tissue culture plates containing the irradiated producer cells (*see*, below).

On day 2, cells were gently harvested to remove them from the adherent producer cells, pelleted, and replated in fresh medium containing IL-4 and GM-CSF, at 7 x 10⁵ cells/ml with 5 ml/well in 6 well tissue culture plates. On day 4, 10 ng rmGM-CSF and 50 ng rmIL-4 were added to each well. On day 6, cells were harvested with gentle pipetting and replated in 100 mm tissue culture dishes 7x10⁵ cell/ml with 10 ml/plate of DC CM supplemented with 20 ng/ml rmGM-CSF and 100 ng/ml rmIL-4. This method consistently yielded a cell population that was 30-50% by morphology and phenotype. On day 7, transduction and function of dendritic cells was confirmed using X-gal staining for β -galactosidase, mixed leukocyte reaction, and specific cytokine release using a β -gal-specific CTL clone.

Producer cells: Ecotropic producer cells were used containing the bgal gene or, as a control, the rat Neu gene under the transcriptional control of the LTR from Moloney

murine leukemia virus (MMLV), using an MMLV backbone. Producer cells were irradiated with 5000 rads and plated at 5×10^5 cells per well in 6 well plates 24 hours prior to addition of murine bone marrow cells for co-cultivation. Producer cells were grown in DMEM/10% bovine calf serum.

- 5 *In Vivo Treatment Studies:* On day 0, 3×10^5 CT26.CL25 cells were injected i.v. into BALB/c mice to establish pulmonary metastases. On days 3 and 6, mice were immunized with transduced bone marrow-derived DC (4×10^5 IV). Mice were sacrificed on day 12 and metastatic lung nodules were enumerated in a randomized and blinded manner.

Statistical Analysis: The Wilcoxon-Mann-Whitney U test was used to examine the null hypothesis of identity of ranks between two sets of data.

Example 4: Gene Transfer into Human Dendritic Cells

Dendritic cells are highly potent antigen presenting cells that are capable of activating quiescent T cells, and which stimulate anti-tumor immune responses.

- Therefore, the ability constitutively to express tumor antigen genes in DC is a powerful method for characterizing new tumor antigens *in vitro* and to actively immunize *in vivo*.
15 However, the growth of large numbers of DC has been difficult, and such cells have not been receptive to gene transfer. Since CD34⁺ hematopoietic progenitor cells (HPC) can be differentiated into DC, human CD34⁺ HPC were retrovirally transduced with tumor antigen genes, followed by *in vitro* differentiation into dendritic cells.

- 20 Human CD34⁺ HPC were retrovirally transduced with the marker gene murine B7-1 by four different methods, followed by differentiation *in vitro* into DC using GM-CSF, TNF- α , and SCF (*see, supra*). The four transduction methods were:

- 1) transduction with supernatant only (no co-culture), and amphotropic retrovirus (PA317); 2) transduction with co-culture with producer line, and amphotropic retrovirus (PA317); 3) transduction with supernatant only (no co-culture), and GALV retrovirus (PG13); and, 4) transduction with co-culture, and GALV retrovirus (PG13). Co-culture and GALV retrovirus improved transduction efficiency, as measured by expression of marker gene by FACS, more than 10 fold in the DC population compared to traditional supernatant and amphotropic transduction

- 30 *Human Dendritic Cell Studies:* Hematopoietic progenitor cells were obtained from melanoma patients pretreated with G-CSF, followed by leukapheresis and isolation of CD34⁺ cells by positive selection on an antibody affinity column. These cells were

successfully transduced with a marker gene as well as the MART-1 and GP100 tumor antigen genes. Following *in vitro* differentiation of the transduced cells into dendritic cells using GM-CSF and TNF α , 25-30% of B7-2+ dendritic cells expressed the marker gene on FACS analysis. Optimal dendritic cell transduction was obtained using co-cultivation with retroviral producer cells which utilize the gibbon ape leukemia virus (GALV) envelope (Table 6), as described *supra*.

Table 6: % Transduction of CD34+ Cells Differentiated to Dendritic Cells

| Retroviral Envelope | Method of Transduction | % of cells expressing marker gene | % of hB7-2+ cells expressing marker gene |
|---------------------|------------------------|-----------------------------------|--|
| Amphotropic (PA317) | Supernatant | 3 | 2 |
| | Co-culture | 12 | 8 |
| GALV (PG13) | Supernatant | 6 | 1 |
| | Co-culture | 38 | 28 |

Example 5: Transduction of Human Dendritic Cells with the MART-1 melanoma antigen gene

Dendritic cells transduced with the MART-1 tumor antigen were recognized by MART-reactive tumor infiltrating lymphocytes (TIL), suggesting that the DC were capable of processing and presenting the foreign gene product (Table 7).

Table 7: Cytokine Release from MART-Reactive TIL in Response to Dendritic Cells Transduced with MART-1 (Tumor Antigen) Gene

| Stimulators | Effectors [H IFN γ ; pg/ml/24 hrs] | |
|---|--|----------------------------------|
| | None | TIL 1235 (MART-reactive T-cells) |
| None | 1 | 155 |
| Dendritic Cells | 3 | 230 |
| Dendritic Cells, transduced with control gene | 2 | 263 |
| Dendritic Cells, transduced with MART-1 | 4 | 1,855 |
| α CD3 (positive control) | 2 | 1,674 |

MART-1 transduced dendritic cells were able to stimulate the production of tumor-specific T-cells from resting lymphocytes. MART-specific T-cells were generated from resting lymphocytes using MART-transduced dendritic cells (Table 8).

Table 8: Cytokine Release from Lymphocytes Stimulated with MART-Transduced Dendritic Cells (hIFN γ ; pg/ml/24 hours)

| Stimulators | Responders Lymphocytes stimulated with: | |
|-------------|--|---------|
| | Control DC | MART DC |
| Media only | 22 | 16 |
| T2 + MART | 41 | 4395 |
| T2 + FLU | 48 | 20 |

Example 6: Transduction of Human Dendritic Cells with the GP100 human melanoma antigen gene

GP100 transduced dendritic cells stimulated the production of tumor-specific T-cells from resting lymphocytes. GP100-specific T-cells were generated from resting lymphocytes using GP100-transduced dendritic cells (Table 9). Significant amounts of IFN γ were released when T-cells generated from GP100 transduced DC were co-cultured with T2 cells pulsed with A2-restricted GP100 peptide epitopes or with A2+ melanoma cells (624.38 mel and SK23 mel), but not with A2- melanoma cells (583 mel), or an A2+, GP100-breast tumor cell line (MDA 231).

Table 9: Cytokine Release from Lymphocytes Stimulated with GP100-Transduced Dendritic Cells (hIFN γ ; pg/ml/24/hrs)

| 5 | Stimulators | A2 | Responders | |
|----|-----------------------------|-----|------------------------------|-------------|
| | | | Lymphocytes stimulated with: | |
| | | | Control (Neo) DC | GP100 DC |
| | Media only | N/A | 99 | 168 |
| | T2+FLU | + | 128 | 234 |
| | T2+M9-27 | + | 140 | 415 |
| | T2+G9-154 | + | 133 | 2980 |
| 10 | T2+G9-209 | + | 160 | 228 |
| | T2+G9-280 | + | 124 | 2352 |
| | 624.38 mel | + | 65 | 2414 |
| | SK23 MEL | + | 36 | 797 |
| | 583 MEL | - | 41 | 41 |
| 15 | MDA231 (breast cancer line) | + | 24 | 42 |

These studies demonstrated that tumor antigen genes were expressed by dendritic cells using retroviral transduction. Transduced dendritic cells are, therefore, valuable reagents for active immunization strategies against cancer and infectious diseases, and are useful *in vitro* to uncover unique tumor epitopes and antigens, and as a tool to study the basic biology of primary dendritic cells. Accordingly, metastatic melanoma patients are immunized with autologous dendritic cells transduced with the MART-1 or GP100 tumor antigen genes to inhibit melanoma metastasis and disease progression.

Example 7: Transduction of Human CD34+ HPC and Differentiation into DC

Human CD34+ HPC were retrovirally transduced with the melanoma tumor antigen gene MART-1 and differentiated *in vitro* into DC using GM-CSF, TNF α , and SCF (*see*, protocols). The MART-1 transduced DC have the same phenotypic and morphological characteristics and they have the same ability to stimulate allogeneic MLR as untransduced DC. In addition, the MART-1 transduced DC stimulated high levels of cytokine release by MART-1 specific tumor infiltrating lymphocytes (*see*, Table 10). This indicates that they were able to express, process, and present a MART-1

epitope on MHC class I molecules. This expression and presentation was stable, persisting beyond two weeks without selection.

Table 10: Cytokine Release from MART-reactive TIL in response to Dendritic Cells Transduced with PG-SAM-MART-EN

| 5 | hIFN- γ (pg/ml/24 hr) | |
|--|------------------------------|----------|
| | Effectors | |
| | Targets | TIL 1235 |
| | 0 | 130 |
| | JDC | 226 |
| 10 | J p12-DC | 184 |
| | J MART-DC | 2,604 |
| | W p12-DC | 200 |
| | W MART-DC | 1,237 |
| | M p12 DC | 193 |
| 15 | M MART DC | 2,816 |
| | SK23 | 19,670 |
| | α CD3 | 4,301 |
| J W and M represent 3 different patients; p12 is control DC transduced with unrelated gene | | |

20

Example 8: Stimulation of Autologous Peripheral Blood Lymphocytes with MART-1-transduced DCs. Because the CD34⁺ HPCs that were transduced with MART-1 and differentiated to DCs were strongly recognized by MART-specific lymphocytes, it was of interest to determine whether the transduced DCs could stimulate quiescent autologous lymphocytes to raise a specific anti-MART CTL response. DCs were transduced with either the MART-1 or control SAM retrovirus, irradiated, and incubated with autologous quiescent T lymphocytes at a 1:10 stimulator: effector ratio. The T cells were restimulated with freshly transduced DCs every two weeks and were tested for MART-1 reactivity one week after each stimulation. Specific cytokine release by lymphocytes against MART-1-expressing targets was not evident after the first restimulation. However, after two restimulations, the lymphocytes stimulated with

30

MART-1-transduced DCs but not SAM-transduced DCs were highly MART-specific in one of three patients tested. Furthermore, they also released cytokine in response to HLA-A2⁺ melanoma cells that express MART-1, but not in response to HLA-A2⁻ melanoma cells or HLA-A2⁺ non-melanoma tumor cells that do not express MART-1.

- 5 The lymphocytes stimulated with MART-DC also exhibited strong and specific lysis of HLA-A2⁺ cells expressing MART-1 (Figure 7). Both the MART-DC- and SAM-DC-stimulated lymphocytes proliferated well, expanding approximately 10-fold each week. These results indicate that CD34⁺ HPCs that are transduced with MART-1 and differentiated into DCs can stimulate the generation of specific anti-MART CTLs from
- 10 autologous quiescent lymphocytes that are highly lytic and release large amounts of cytokine in response to HLA-matched MART peptide-pulsed cells and melanoma cells.

DCs were transduced with either the MART-1 or control SAM retrovirus as described *supra*, irradiated (1500 cGy), and incubated with autologous quiescent T lymphocytes at a 1:10 stimulator: effector ratio. IL-2 (300 IU/ml) was added on day 2.

- 15 The T cells were restimulated with freshly transduced DCs in this manner every two weeks and were tested for MART-1 reactivity one week after each stimulation. After two restimulations, the lymphocytes were tested for their ability to recognize various cells. These cells included T2 cells pulsed either with the MART₂₇₋₃₅ or irrelevant influenza M1 peptide, the HLA-A2⁺ melanoma lines 624.38 mel and SK23 mel, the HLA-A2⁻
- 20 melanoma line 586 mel, and the HLA-A2⁺ breast cancer line MDA231, which does not express MART-1. OKT3 is a positive control in which the plate is coated with antibody against the T-cell receptor complex. Results are expressed as the mean \pm SEM.

Table 11: Cytokine Release from Lymphocytes Stimulated With Mart-Transduced DCs.

| | Stimulators | Responders | | | |
|----|-------------|-----------------------|---------------|----------------|------------|
| | | None | SAM-DC PBL | MART-DC PBL | 1235 TIL |
| 5 | 0 | 0 ± 0.05 ^a | 22 ± 2 | 16 ± 1 | 94 ± 4 |
| | T2 + MART | 0 ± 0.06 | 41 ± 1 | 4400 ± 300 | 2800 ± 100 |
| | T2 + FLU | 3 ± 0.1 | 48 ± 2 | 20 ± 2 | 45 ± 0.4 |
| | 624.38 mel | 0 ± 0.01 | 9 ± 0.2 | 702 ± 2 | 2500 ± 200 |
| 10 | SK23 mel | 0 ± 0.06 | 6 ± 0.3 | 1400 ± 100 | 5400 ± 200 |
| | 586 mel | 1 ± 0.1 | 10 ± 0.8 | 18 ± 1 | 29 ± 3 |
| | MDA231 | 0 ± 0.04 | 5 ± 0.1 | 7 ± 0.1 | 104 ± 7 |
| | OKT3 | 0 ± 0.09 | 1200 ± 100 | 660 ± 30 | 2000 ± 200 |

^aHuman INF- γ (pg/ml/24 h).**15 Protocols****Retroviruses and Packaging Lines**

All retroviral constructs are based on the SAM-EN construct (*Blood* (1995) 85:139-145). In brief, the gene of interest (murine B7-1, beta-galactosidase, MART-1) was cloned into the multiple cloning site of the retroviral plasmid pSAMEN. The

20 amphotropic retroviral producer lines were constructed by a micro-ping-pong technique involving transfection of the retroviral plasmid into a mixture of PA317 (amphotropic) (*Mol. Cell. Biol.* (1986) 6:2895-2902) and GP+E86 (ecotropic) (*J. Virol* (1988) 62:1120) packaging cell lines, followed by overgrowth of the amphotropic line. The Gibbon Ape leukemia virus (GALV) retroviral producer lines were constructed by transduction of the

25 PG13 (Gibbon Ape) (*J. Virol.* (1991) 65:2220-2224) packaging line with supernatant from the appropriate amphotropic producer cells.

Isolation of Human CD34+ HPC

Patients were treated with G-CSF for 5 days, followed by leukapheresis. CD34+ cells were selected using an immunoaffinity column from CellPro (Bothell, WA)

30 according to the manufacturer's directions. CD34+ cells were washed with PBS and cryopreserved in 90% human male AB serum (Sigma, St. Louis) and 10% DMSO.

Transduction of Human CD34+ HPC and Differentiation into Dendritic Cells

1. *Thaw CD34+ cells:* On day 0, CD34+ cells thawed into 20 ml CM, counted, centrifuged (2000 rpm, RT), resuspended in 5 ml DC CM in 6 well plates at 5×10^5 cells/well.
- 5 2. *Transduction:* On day 1, cells transduced for 6 hrs by resuspending cells (2000 rpm, RT) in 2.5 ml CM containing 2x DC cytokines and polybrene (1x polybrene = 8 mg/ml). 2.5 ml of retroviral supernatant (see b below) combined with cell suspension in 6 well plate that has irradiated producer line monolayer (see a below). Plates centrifuged (2500 rpm, 32°C, 1 hr), and incubated for 5 hrs in CO₂ incubator at 37°C. Transduction
- 10 stopped by resuspending cells (2000 rpm, RT) in 5 ml DC CM, and incubating 18 hrs in CO₂ incubator at 37°C. This completes one transduction cycle.
 - a. *Production of Co-Culture Monolayer:* Producer cell line (PA317 or PG13-based) harvested by trypsinization, irradiated to 3000 rads. Irradiated cells plated at 7×10^5 cells/well in supernatant CM in 6 well plates the night before transduction. If
 - 15 the irradiated producer cells look ragged, fresh monolayers of irradiated producer cells were made in new wells for each cycle of transduction. Typically, one monolayer was used for the first two transduction cycles, and a new monolayer was used for the third cycle (to balance cell loss from transferring to new monolayers with the monolayer being in good shape).
 - 20 b. *Production of Supernatant:* Retroviral producer lines grown to near-confluency in T-175 flasks. Medium removed, and 30 ml supernatant CM replaced. Flasks were then incubated for 12-16 hrs in CO₂ incubator at 32°C. Medium removed and filtered through .45 mm filter, and then either used directly or refrigerated (never more than 3 days) until use.
- 25 3. *Retransduction:* On days 2 and 3, cells transduced a second and third time by repeating the transduction cycle outlined in #2 above.
4. *Cell Growth:* Cells grown in 5 ml/well DC CM (in 6 well plate) until day 12 when they are used. 1/2 medium changed, and nonadherent cells transferred to new plates on day 8. Notes: 1. CM = [Iscove's medium + 10% hu AB, abx, gln], except during the
- 30 six hours of transduction in the three cycles--then 10% FCS is used in place of 10% hu AB. 2. DC CM = CM with GM-CSF (100 ng/ml), TNF- α (100 ng/ml), and SCF (20

ng/ml; activity: ED₅₀=2.5 ng/ml) 3. Supernatant CM = DM EM + 10% FBS, abx, gln.

MLR Assay

Allogeneic T cells were prepared from PBMC by negative selection on an
5 TCC-1000 immunoaffinity column according to the manufacturer's instructions (R&D, Minneapolis, MN). Allogeneic PBMC or DC from the same donor were irradiated to 1500 rad. T cells (1.5×10^5) were added to flat bottom 96 well plates, along with varying numbers of irradiated PBMC or DC. Four days later, the cells were pulsed with 1 mCi [³H]thymidine, and cell proliferation was estimated 8 hours later by measuring the
10 incorporation of radioactivity into DNA (Betaplate, Pharmacia LKB, Gaithersburg, MD).

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference in its entirety for
15 all purposes. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications are made thereto without departing from the spirit or scope of the appended claims.

WHAT IS CLAIMED IS:

- 1 1. A method of making a dendritic cell transduced with a selected
2 nucleic acid, comprising:
3 transducing a hematopoietic stem cell with the selected nucleic acid; and
4 differentiating the transduced stem cell into a dendritic cell, thereby making a
5 dendritic cell transduced with the selected nucleic acid.
- 1 2. The method of claim 1, wherein the stem cell is a CD34⁺ stem cell.
- 1 3. The method of claim 1, wherein the stem cell is a CD34⁺ stem cell,
2 wherein the stem cell is negative for MHC class II antigens.
- 1 4. The method of claim 1, wherein the stem cell is differentiated into a
2 dendritic cell *in vitro*.
- 1 5. The method of claim 1, wherein the stem cell is differentiated into a
2 dendritic cell *in vitro*, wherein the stem cell is differentiated into a dendritic cell by
3 contacting the stem cell with lipofectamine and a cytokine selected from the group
4 consisting of murine GM-CSF, human GM-CSF, IL-4, SCF, Flt3, and TNF- α , and
5 wherein the method further comprises titrating the cytokines to determine the
6 concentration of the cytokine which provides optimal differentiation.
- 1 6. A method of activating a T cell, comprising contacting the T cell
2 with a dendritic cell, wherein the dendritic cell expresses an antigenic protein encoded by
3 a recombinant nucleic acid, wherein the recombinant nucleic acid is expressed in the
4 dendritic cell.
- 1 7. The method of claim 6, wherein the dendritic cell contacts the T
2 cell *in vitro*.

1 **8.** The method of claim 6, wherein the antigenic protein comprises a
2 peptide subsequence derived from a peptide expressed on the surface of a cancer cell.

1 **9.** The method of claim 8, wherein the activated T cell is competent to
2 kill the cancer cell.

1 **10.** A recombinant dendritic cell which comprises a recombinant
2 expression cassette, which expression cassette encodes an antigenic peptide.

1 **11.** The recombinant dendritic cell of claim 10, wherein the
2 recombinant expression cassette was transduced into a stem cell using a retroviral vector,
3 which stem cell was differentiated into the dendritic cell.

1 **12.** The recombinant dendritic cell of claim 10, wherein the dendritic
2 cell is a primary cell.

1 **13.** The recombinant dendritic cell of claim 10, wherein the antigenic
2 peptide is encoded in the expression cassette as a subsequence of a full length protein
3 encoded by the expression cassette.

1 **14.** The recombinant dendritic cell of claim 10, wherein the antigenic
2 peptide is derived from a protein selected from the group of antigenic proteins consisting
3 of HER-2, MART-1, gp-100, PSA, HBVc, HBVs, tyrosinase, MAGE-1, trp-1 and CEA.

1 **15.** The recombinant dendritic cell of claim 10, wherein the
2 recombinant cell further comprises a recombinant expression cassette encoding a cytokine.

1 **16.** The recombinant dendritic cell of claim 10, wherein the
2 recombinant cell further comprises a recombinant expression cassette encoding a cytokine
3 selected from the group consisting of GM-CSF, IL-2, and TNF.

1 17. The recombinant dendritic cell of claim 10, wherein the
2 recombinant cell further comprises a recombinant expression cassette encoding a cell
3 receptor ligand.

1 18. A recombinant dendritic cell which comprises a recombinant
2 expression cassette, which expression cassette encodes a protein selected from the group
3 consisting of a cytokine, a cell receptor ligand, and, a subsequence of a cytokine protein.

1 19. The recombinant dendritic cell of claim 18, wherein the cell further
2 comprises an antigenic peptide.

1 20. The recombinant dendritic cell of claim 18, wherein the cell further
2 comprises an antigenic peptide derived from a protein selected from the group of
3 antigenic proteins consisting of HER-2, MART-1, gp-100, PSA, HBVc, HBVs,
4 tyrosinase, MAGE-1, trp-1 and CEA.

1 21. A cell culture for making recombinant dendritic cells comprising a
2 recombinant stem cell and GM-CSF.

1 22. The cell culture of claim 21, wherein the GM-CSF is selected from
2 the group consisting of murine GM-CSF, and human GM-CSF.

1 23. The cell culture of claim 21, further comprising a cytokine selected
2 from the group consisting of TNF- α , SCF, Flt3 and IL-4.

1 24. The cell culture of claim 21, wherein the GM-CSF is provided at a
2 concentration of at least about 2 ng/ml.

1 25. The cell culture of claim 21, wherein the GM-CSF is provided at a
2 concentration of at least about 20 ng/ml.

1 **26.** The cell culture of claim 21, wherein the GM-CSF is provided at a
2 concentration of at least about 100 ng/ml.

1 **27.** The cell culture of claim 21, wherein the GM-CSF is provided at a
2 concentration of between 20 ng/ml and about 200 ng/ml, and wherein the culture further
3 comprises a second cytokine selected from the group consisting of TNF- α , SCF, Flt3 and
4 IL-4, wherein the concentration of the second cytokine is between about 20 ng/ml and
5 200 ng/ml .

1 **28.** The cell culture of claim 21, wherein the recombinant stem cell is a
2 recombinant human CD34⁺ stem cell.

1 **29.** A method for detecting T cell mediated anti-cancer cell activity of a
2 target antigenic peptide, comprising:
3 transforming a dendritic cell with a recombinant expression cassette comprising a
4 nucleic acid encoding the target antigenic peptide, thereby providing a transformed
5 dendritic cell;
6 contacting a T cell with the transformed dendritic cell, thereby providing an
7 activated T cell;
8 contacting a cancer cell with the activated T cell; and,
9 monitoring the effect of the activated T cell on the cancer cell, thereby detecting
10 the anti-cancer cell activity of the target antigenic peptide.

1 **30.** The method of claim 29, wherein the step of transforming the
2 dendritic cell is performed by transforming a stem cell with the recombinant expression
3 cassette and differentiating the stem cell into the dendritic cell.

1 **31.** The method of claim 29, wherein the antigenic peptide is a
2 subsequence of a protein encoded by the recombinant expression cassette.

1 **32.** The method of claim 29, wherein the antigenic peptide is derived
2 from HER-2, and the cancer cell is a breast cancer cell.

1 33. The method of claim 29, wherein the antigenic peptide is derived
2 from a protein selected from the group consisting of MART-1 and gp-100, wherein the
3 cancer cell is a melanoma cell.

1 34. The method of claim 29, wherein the antigenic peptide is derived
2 from CEA and the cancer cell is a colon cancer cell.

1 35. The method of claim 29, wherein the T cell is contacted with the
2 dendritic cell *in vivo*.

1 36. The method of claim 29, wherein the T cell is contacted with the
2 dendritic cell *in vitro*.

1 37. The method of claim 29, wherein the T cell is contacted with the
2 dendritic cell *in vitro* and contacted with the cancer cell *in vitro*.

1 38. The method of claim 29, wherein the T cell is contacted with the
2 dendritic cell *in vivo* and contacted with the cancer cell *in vivo*.

1 39. A method of killing a target cell, comprising contacting the target
2 cell with an activated T cell, wherein the T cell is activated by contacting the T-cell with
3 a dendritic cell expressing an antigenic peptide encoded by a recombinant expression
4 cassette in the dendritic cell.

1 40. The method of claim 39, wherein the target cell is contacted by the
2 activated T cell *in vivo*.

1 41. The method of claim 39, wherein the target cell is contacted by the
2 activated T cell *in vitro*.

1 **42.** The method of claim 39, wherein the target cell is selected from the
2 group consisting of a cancer cell, an intracellularly infected with a bacterial cell, and, a
3 virally-infected cell.

1 **43.** A method of altering the MHC class II antigenic repertoire of a
2 dendritic cell comprising transducing the dendritic cell with an expression cassette, which
3 expression cassette comprises a nucleic acid encoding a heterologous protein, and
4 expressing the heterologous protein in the dendritic cell.

1 **44.** The method of claim 43, wherein the dendritic cell is a human cell.

1 **45.** The method of claim 43, wherein the heterologous protein is
2 selected from the group of proteins consisting of HER-2, MART-1, gp-100, PSA, HBVc,
3 HBVs, tyrosinase, MAGE-1, trp-1 and CEA.


1 **46.** A pharmaceutical composition comprising a pharmaceutically
2 acceptable carrier and a recombinant dendritic cell which expresses a heterologous
3 protein, which recombinant dendritic cell is competent to activate a T cell to kill a target
4 cell *in vivo*.

1 **47.** The pharmaceutical composition of claim 46, wherein the
2 heterologous protein is selected from the group of proteins consisting of HER-2, MART-
3 1, gp-100, PSA, HBVc, HBVs, tyrosinase, MAGE-1, trp-1 and CEA.

1 **48.** The pharmaceutical composition of claim 46, further comprising a T
2 cell.

1 **49.** The pharmaceutical composition of claim 46, wherein the target cell
2 is a cancer cell.

1/6




- DC 200 ng/ml GM-CSF
- ▲ DC 2 ng/ml GM-CSF
- ◆ SPLENOCYTES
- DC 20 ng/ml GM-CSF
- ▼ DC 0.2 ng/ml GM-CSF

FIG. 1.

SUBSTITUTE SHEET (RULE 26)

2/6

**FIG. 2.**

SUBSTITUTE SHEET (RULE 26)

1 TNAGGATGTC GTCAAGAAGA AGNGCCAGGT TTCCGGGCCT CACATTGNCA NAAGACGGGA ATATGGTGGA 70
71 AAATAACATA TAGACAAACG CACACCGGCC TTATTCCAAG CGGNTTCGGC CAGTAACGTT AGGGGGGGG 140
141 GGAATTGAT CCCGCTCGAA CTGCTAGCGG ACCTACTAA ATTTTAACAC TGACTIONA TTAGAGATGG 210
211 NTTGNATTT TCCTACACCA TTCCAAAGGA GAACATTAGA TGTCTGTATT AAATTCAAGC AAAAGTGTGA 280
281 GAGAAATAAT TTCAGCATGT CTCAGGTGTC TCGCTGGCTC TTAAGGTGAA TAAGGTGGTG GTGACTGTTC 350
351 TGCAGAGAGT TTCTCATAAG CAGGTGGAGC ATTGGGAACA CAGGTTTCTT TGAAGAGACA 420
421 CTTTGNTGTC CCNATGATCA AACCCTTCTT GTGGGCATCT TCTTGTTAAG GCACATTGAG TGNACACATGA 490
491 AGACTTTTAT CCATCAAGGG TCTGTATCCA TTCGGCTTCT TCAATACCAC AGCCCATGAG CAGGAAGATC 560
561 CAGGNCATG TCAAGATGCC GTCCCNNGG GCTCTCCANC NNNNGTAAG AGTGCCCNCG CCTCTTGGG 630
631 GNACCATGGT GAAGGGAGAT TTCTCTTNGA TNTNTGGGC AAAGGANAAG AAACCCCTN ATANAGNCCC 700
701 TTCTTTTNNC GGATGGGAAT NGCCCCGAGG GNCCCCCGNT TCGTGGGGCC NCNAANNNG AGGTTGGCCC 770
771 CCCCCGGGTG GGAAGCTNCA CNTNGGGGGG NNTTCCCCCN 840

3/6

FIG. 3.

SUBSTITUTE SHEET (RULE 26)

4/6




FIG. 4.





FIG. 5.







SUBSTITUTE SHEET (RULE 26)

5/6

**FIG. 6.**

SUBSTITUTE SHEET (RULE 26)

6/6

**FIG. 7A.****FIG. 7B.****FIG. 7C.****FIG. 7D.****FIG. 7E.****FIG. 7F.**

SUBSTITUTE SHEET (RULE 26)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|--|
| (51) International Patent Classification ⁶ : C12N 5/10, A61K 48/00, C12N 15/12, 15/26, 15/28, G01N 33/50 | A3 | (11) International Publication Number: WO 97/29183 (43) International Publication Date: 14 August 1997 (14.08.97) |
| (21) International Application Number: PCT/US97/02063 (22) International Filing Date: 7 February 1997 (07.02.97) (30) Priority Data: 60/011,433 8 February 1996 (08.02.96) US (60) Parent Application or Grant (63) Related by Continuation US 60/011,433 (CIP) Filed on 8 February 1996 (08.02.96) (71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Bethesda, MD 20892 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): HWU, Patrick [US/US]; 11419 Commonwealth Drive #202, Rockville, MD 20852 (US). REEVES, Mark [US/US]; 23180 Palm Avenue, Grand Terrace, CA 92313 (US). ROSENBERG, Steven, A. [US/US]; 10104 Inn Gate Road, Potomac, MD 20854 (US). | | (74) Agents: WEBER, Kenneth, A. et al.; Townsend and Townsend and Crew L.L.P., 8th floor, Two Embarcadero Center, San Francisco, CA 94111 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 18 December 1997 (18.12.97) |
| (54) Title: METHODS AND COMPOSITIONS FOR TRANSFORMING DENDRITIC CELLS AND ACTIVATING T CELLS (57) Abstract <p>Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen presenting cell which activates T cells against MHC class I-antigen targets. Kits, assays and therapeutics are based upon the activation of T cells by the recombinant dendritic cell. Cancer, viral infections and parasitic infections are all ameliorated by the recombinant dendritic cells, or corresponding activated T cells. Therapeutic compositions and pharmaceutical compositions are provided.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AM | Armenia | GB | United Kingdom | MW | Malawi |
| AT | Austria | GE | Georgia | MX | Mexico |
| AU | Australia | GN | Guinea | NE | Niger |
| BB | Barbados | GR | Greece | NL | Netherlands |
| BE | Belgium | HU | Hungary | NO | Norway |
| BF | Burkina Faso | IE | Ireland | NZ | New Zealand |
| BG | Bulgaria | IT | Italy | PL | Poland |
| BJ | Benin | JP | Japan | PT | Portugal |
| BR | Brazil | KE | Kenya | RO | Romania |
| BY | Belarus | KG | Kyrgyzstan | RU | Russian Federation |
| CA | Canada | KP | Democratic People's Republic of Korea | SD | Sudan |
| CF | Central African Republic | KR | Republic of Korea | SE | Sweden |
| CG | Congo | KZ | Kazakhstan | SG | Singapore |
| CH | Switzerland | LI | Liechtenstein | SI | Slovenia |
| CI | Côte d'Ivoire | LK | Sri Lanka | SK | Slovakia |
| CM | Cameroon | LR | Liberia | SN | Senegal |
| CN | China | LT | Lithuania | SZ | Swaziland |
| CS | Czechoslovakia | LU | Luxembourg | TD | Chad |
| CZ | Czech Republic | LV | Latvia | TG | Togo |
| DE | Germany | MC | Monaco | TJ | Tajikistan |
| DK | Denmark | MD | Republic of Moldova | TT | Trinidad and Tobago |
| EE | Estonia | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | UG | Uganda |
| FI | Finland | MN | Mongolia | US | United States of America |
| FR | France | MR | Mauritania | UZ | Uzbekistan |
| GA | Gabon | | | VN | Viet Nam |

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/02063

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N5/10 A61K48/00 C12N15/12 C12N15/26 C12N15/28
G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | WO 95 34676 A (SYSTEMIX INC ;GALY ANNE H M (US); MULE JAMES J (US)) 21 December 1995 | 1-4, 21-31 |
| Y | see page 22 - page 30; claims 9,10,24,28 | 5 |
| | --- | |
| Y | WO 94 27435 A (LIFE TECHNOLOGIES INC) 8 December 1994 | 5 |
| | see claims 1,2 | |
| | --- | |
| | -/-- | |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

24 October 1997

Date of mailing of the international search report

10.11.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Gurdjian, D

INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/US 97/02063

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|--|
| X | HEEMSKERK MH ET AL: "Melanoma-specific CTL, generated in vitro using dendritic cells expressing melanoma associated antigens (Meeting abstract)." GENE THERAPY OF CANCER: 2ND EUROPEAN CONFERENCE, SEPTEMBER 7-8, 1995, LONDON, A13, 1995, XP000675471 | 6-14,29, 31,33 |
| Y | see the whole document | 15-20, 32,34, 36,37, 39,41-49 |
| X | ROUSE RJ ET AL: "Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins." J VIROL, SEP 1994, 68 (9) P5685-9, UNITED STATES, XP000645186 see the whole document | 6,7, 10-13, 39, 41-44, 46,48 |
| Y | CONRY R M ET AL: "SELECTED STRATEGIES TO AUGMENT POLYNUCLEOTIDE IMMUNIZATION" GENE THERAPY, vol. 3, no. 1, January 1996, pages 67-74, XP002035090 see the whole document | 15-20, 32,34, 36,37, 39,41-49 |
| A | WO 95 06120 A (RHONE POULENC RORER SA ;INST NAT SANTE RECH MED (FR); HADDADA HEDI) 2 March 1995 see claims 1-23 | 1-5, 21-28 |
| A | BAKKER AB ET AL: "Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro." CANCER RES;55(22):5330-4 1995, XP002032191 see the whole document | 1-4, 21-28 |
| A | EP 0 563 485 A (SCHERING PLOUGH CORP) 6 October 1993 see the whole document | 1-5, 21-28 |
| A | WO 93 18137 A (SYSTEMIX INC) 16 September 1993 see line 1-20 | 1-5 |
| A | BOEHMELT G ET AL: "Dendritic cell progenitor is transformed by a conditional v-Rel estrogen receptor fusion protein v-RelER." CELL, JAN 27 1995, 80 (2) P341-52, UNITED STATES, XP002000729 see the whole document | 1-4,6,7, 10-13, 21-28, 39, 41-44, 46-48 |

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/02063

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|--|
| A | CHEN BP ET AL: "Cytokine-mobilized peripheral blood CD34+Thy-1+Lin- human hematopoietic stem cells as target cells for transplantation-based gene therapy." LEUKEMIA, OCT 1995, 9 SUPPL 1 PS17-25, ENGLAND, XP000674363 see the whole document --- | 1-5 |
| A | WO 94 16716 A (VIROGENETICS CORP) see page 114 - page 170 --- | 15-20, 32,34, 36,37, 39,41-49 |
| P,X | REEVES, MARK E. ET AL: "Retroviral transduction of human dendritic cells with a tumor-associated antigen gene" CANCER RES. (1996), 56(24), 5672-5677 CODEN: CNREA8;ISSN: 0008-5472, XP002032192 see the whole document --- | 1-34,36, 37,39, 41-49 |
| P,X | WO 97 03703 A (RHONE POULENC RORER PHARMA ;PHILIP RAMILA (US); LEBKOWSKI JANE S () 6 February 1997 see the whole document ----- | 1-34,36, 37,39, 41-49 |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/ 02063

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1-3,5,6,8,9 partially as far as they concern an in vivo method and claims 35,38,40 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See annex.

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA210

Subject 1) Claims 1-5, 21-28:

A method of making dendritic cells transduced with nucleic acids and cell structure for the differentiation of transduced haematopoietic cells to dendritic cells.

Subject 1) Claims 6-20, 29-49:

Recombinant dendritic cells with antigenic peptides, cytokines or a ligand and their use for activation of T-cells, killing of a target cell, detection of T-cell mediated anti-cancer activity of a target antigenic peptide, alteration of the MHC class II antigenic repertoire of dendritic cells and their use in pharmaceutical compositions.

INTERNATIONAL SEARCH REPORT

information on patent family members

Interr. Application No

PCT/US 97/02063

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|--|--|
| WO 9534676 A | 21-12-95 | AU 2158295 A EP 0765398 A AU 679120 B AU 7721194 A EP 0716570 A | 05-01-96 02-04-97 19-06-97 22-03-95 19-06-96 |
| WO 9427435 A | 08-12-94 | EP 0702516 A JP 9500013 T | 27-03-96 07-01-97 |
| WO 9506120 A | 02-03-95 | FR 2709309 A AU 7539894 A EP 0719332 A FI 960855 A JP 9501837 T NO 960743 A ZA 9406264 A | 03-03-95 21-03-95 03-07-96 23-04-96 25-02-97 25-03-96 20-03-95 |
| EP 0563485 A | 06-10-93 | AU 682466 B AU 3928993 A CA 2133316 A EP 0633930 A JP 7505527 T MX 9301753 A NZ 251585 A WO 9320186 A | 09-10-97 08-11-93 14-10-93 18-01-95 22-06-95 01-09-93 27-07-97 14-10-93 |
| WO 9318137 A | 16-09-93 | AU 680406 B CA 2131368 A EP 0631618 A JP 7504331 T | 31-07-97 16-09-93 04-01-95 18-05-95 |
| WO 9416716 A | 04-08-94 | AU 6165294 A CA 2153336 A EP 0680331 A JP 9503902 T | 15-08-94 04-08-94 08-11-95 22-04-97 |
| WO 9703703 A | 06-02-97 | AU 6504596 A | 18-02-97 |